MORPHOGENIC PROTEIN SOLUBLE COMPLEX AND COMPOSITION THEREOF

Abstract: Disclosed are compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.

Description: MORPHOGENIC PROTEIN SOLUBLE COMPLEX AND COMPOSITION THEREOF. Field of the Invention The present invention relates generally to morphogenic proteins and, more particularly, to compositions having improved solubility in aqueous solvents. Background of the Invention Morphogenic proteins ("morphogens") are well known and described in the art. See, for example, U.S. Pat. Nos. 4, 968,590; 5,011,691; 5,018,753; PCT US92/01968 and PCT US92/07432; e. well as various articles published in the scientific literature, including Ozkaynak et al. (1992) J.Biol. Chem. 267:25220-25227 and Ozkaynak et 1. (1991) Biochem. Biophys. Res. Comm. 179:116-123. The art has described how to isolate morphogenic proteins from bone, how to identify genes encoding these proteins and how to express them using recombinant DNA technology. The morphogenic proteins are capable of inducing endochondral bone formation and other tissue formation in a mammal when they are properly folded, dimerized and disulfide bonded to produce a dimeric species having the appropriate three dimensional conformation. The proteins have utility in therapeutic applications, either by direct or systemic administration. Where bone induction is desired, for example, the morphogen typically is provided to the desired site for bone formation in a mammal in association with a suitable matrix having the appropriate conformation to allow the infiltration, proliferation and differentiation of migrating progenitor cells. The morphogenic protein adsorbed to the surfaces of a suitable matrix is generally referred to in the art as an osteogenic device. The proteins can be isolated from bone or, preferably, the gene encoding the protein is produced recombinantly in a suitable host cell. The morphogen precursor polypeptide chains share a common structural motif, including a N-terminal signal sequence and pro region, both of which are cleaved to produce a mature sequence, capable of disulfide bonding and comprising an N-terminal extension and a C-terminal domain whose amino acid sequence is highly conserved among members of the family. In their mature dimeric forms, the morphogens typically are fairly insoluble under physiological conditions. Increasing the solubility of these proteins has significant medical utility as it would enhance systemic administration of morphogens as therapeutics. Various carrier proteins, including serum albumin and casein are known to increase the solubility of morphogens (see, for example, PCT US92/07432). PCT US92/05309 (WO 93/00050) discusses the use of various solubilizing agents, including various amino acids and methyl esters thereof, as well as guanidine, sodium chloride and heparin, to increase the solubility of mature dimeric BMP2. " Improved methods for the recombinant expression of morphogenic proteins is an ongoing effort in the art. It is an object of this invention to provide an improvement in the methods for producing and purifying morphogenic proteins having high specific activity, and for formulating compositions and osteogenic devices comprising these proteins. Another object is to provide soluble forms of morphogenic proteins consisting essentially of amino acid sequences derived from morphogenic proteins. Another object is to provide formulations which stabilize the soluble complex of morphogenic proteins. Still another object is to provide means for distinguishing between soluble forms of the protein and the mature morphogenic species, to provide means for quantitating the amounts of these proteins in a fluid, including a body fluid, such as serum, cerebro-sprinal fluid or peritoneal fluid, and to provide polyclonal and monoclonal antibodies capable of distinguishing between these various species. Another object is to provide antibodies and biological diagnostic assays for monitoring the concentration of morphogens and endogenous anti-morphogen antibodies present in a body fluid and to provide kits and assays for detecting fluctuations in the concentrations of these proteins in a body fluid. U.S. Patent No. 4,857,456 and Urist et al. (1984) Proc. Soc. Exp. Biol. Med. 176:472-475 describe a serum assay for detecting a protein purported to be a bone morphogenetic protein. The protein is not a member of the morphogen family of proteins described herein, differing in molecular weight, structural characteristics and solubility from these proteins. Summary of the Invention It now has been discovered that morphogenic protein secreted into cultured medium from mammalian cells contains as a significant fraction of the secreted protein a soluble form of the protein, and that this soluble form comprises the mature dimeric species, including truncated forms thereof, noncovalently associated with at least one, and preferably two pro domains. It further has been discovered that antibodies can be used to discriminate between these two forms of the protein. These antibodies may be used as part of a purification scheme to selectively isolate the mature or the soluble form of morphogenic protein, as well as to quantitate the amount of mature and soluble forms produced. These antibodies also may be used as part of diagnostic treatments to monitor the concentration of morphogenic proteins in solution in a body and to detect fluctuations in the concentration of the proteins in their various forms. The antibodies and proteins also may be used in diagnostic assays to detect and monitor concentrations of endogenous anti-morphogen antibodies to the various forms of these proteins in the body. An important embodiment of the invention-is a dimeric protein comprising a pair of polypeptide subunits associated to define a dimeric structure having morphogenic activity. As defined herein and in parent, related applications, morphogens generally are capable of all of the following biological functions in a morphogenically permissive environment: stimulating proliferation of progenitor cells; stimulating the differentiation of progenitor cells; stimulating the proliferation of differentiated cells; and supporting the growth and maintenance of differentiated cells. Each of the subunits of the dimeric morphogenic protein comprises at least the 100 amino acid peptide sequence having the pattern of seven or more cysteine residues characteristic of the morphogen family. Preferably, at least one of the subunits comprises the mature form of a subunit of a member of the morphogen family, or an allelic, species, chimeric or other sequence variant thereof, noncovalently complexed with a peptide comprising part or all of a pro region of a member of the morphogen family, or an allelic, species, chimeric or other sequence variant thereof. The pair of subunits and one or, preferably, two pro region peptides, together form a complex which is more soluble in aqueous solvents than the uncomplexed pair of subunits. Preferably, both subunits comprise a mature form of a subunit of a member of the morphogen family or an allelic, species, chimeric or other sequence variant thereof, and both subunits are noncovalently complexed with a peptide comprising a pro region, or a fragment thereof. Most preferably, each subunit is the mature form of human OP-1, or a species, allelic or other sequence variant thereof, and the pro region peptide is the entire or partial sequence of the pro region of human OP-1, or a species, allelic, chimeric or other sequence variant thereof. Currently, preferred pro regions are full length forms of the pro region. Pro region fragments preferably include the first 18 amino acids of the pro sequence. Other useful pro region fragments are truncated sequences of the intact pro region sequence, the truncation occurring at the proteolytic cleavage site Arg-Xaa-Xaa-Arg. As will be appreciated by those having ordinary skill in the art, useful sequences encoding the pro region may be obtained from genetic sequences encoding known morphogens. Alternatively, chimeric pro regions can be constructed from the sequences of one or more known morphogens. Still another option is to create a synthetic sequence variant of one or more known pro region sequences. As used herein, the mature form of a morphogen protein subunit includes the intact C-terminal domain and intact or truncated forms of the N-terminal extensions. For example, useful mature forms of OP-1 include dimeric species defined by residues 293-431 of Seq ID No. 1, as well as truncated sequences thereof, including sequences defined by residues 300-431, 313-431, 315-431, 316-431 and 318-431. Note that this last sequence retains only about the last 10 residues of the N-terminal extension sequence. Fig. 2 presents the N-terminal extensions for a number of preferred morphogen sequences. Canonical Arg-Xaa-Xaa-Arg cleavage sites where truncation may occur are boxed or underlined in the figure. As will be appreciated by those having ordinary skill in the art, mature dimeric species may include subunit combinations having different N-terminal truncations. Other soluble forms of morphogens include dimers of the uncleaved pro forms of these proteins (see below), as well as "hemi-dimers" wherein one subunit of the dimer is an uncleaved pro form of the protein, and the other subunit comprises the mature form of the protein, including truncated forms thereof, preferably noncovalently associated with a cleaved pro domain. The soluble proteins of this invention also are useful in the formation of therapeutic compositions for administration to a mammal, particularly a human, and for the development of biological assays for monitoring the concentration of these proteins and endogenous antibodies to these proteins in cell samples and body fluids, including, but not limited to, serum, cerebrospinal fluid and peritoneal fluid. The foregoing and other objects, features and advantages of the present invention will be made more apparent from the following detailed description of the invention. Brief Description of the Drawings Fig. 1 is a schematic representation of a morphogen polypeptide chain as expressed from a nucleic acid encoding the sequence, wherein the cross-hatched region represents the signal sequence; the stippled region represents the pro domain; the hatched region represents the N-terminus ("N-terminal extension") of the mature protein sequence; and the open region represents the C-terminal region of the mature protein sequence defining the conserved seven cysteine domain, the conserved cysteines being indicated by vertical hatched lines; Fig.2 lists the sequences of the N-terminal extensions of the mature forms of various morphogens; and Fig. 3 is a gel filtration column elution profile of a soluble morphogen (OP-1) produced and purified from a mammalian cell culture by IMAC, S-Sepharose and S-200HR chromatography in TBS (Tris-buffered saline), wherein V is the void volume, ADH is alcohol dehydrogenase (MW 150 kDa), BSA is bovine serum albumin (MW 67 kDa), CA is carbonic anhydrase (MW 29kDa) and CytC is cytochrome C (MW 12.5 kDa). Detailed Description A soluble form of morphogenic proteins now has been discovered wherein the proteins consist essentially of the amino acid sequence of the protein. The soluble form is a non-covalently associated complex comprising the pro domain or a fragment thereof, noncovalently associated or complexed with a dimeric protein species having morphogenic activity, each polypeptide of the dimer having less than 200 amino acids and comprising at least the C-terminal six, and preferably seven cysteine skeleton defined by residues 330-431 and 335-431, respectively, of Seq. ID No. 1. Preferably, the polypeptide chains of the dimeric species comprise the mature forms of these sequences, or truncated forms thereof. Preferred truncated forms comprise the intact C-terminal domain and at least 10 amino acids of the N- terminal extension sequence. The soluble forms of these morphogenic proteins may be isolated from cultured cell medium, a mammalian body fluid, or may be formulated in vitro. In vivo, under physiological conditions, the pro domain may serve to enhance the transportability of the proteins, and/or to protect the proteins from proteases and scavenger molecules, including antibodies. The pro domains also may aid in targeting the proteins to a particular tissue and/or to present the morphogen to a morphogen cell surface receptor by interaction with a co-receptor molecule. The isolated proteins may be used in therapeutic formulations, particularly for oral or parenteral administration, and in the development of diagnostic and other tissue evaluating kits and assays to monitor the level of endogenous morphogens and endogenous anti-morphogen antibodies. Detailed descriptions of the utility of these morphogens in therapies to regenerate lost or damaged tissues and/or to inhibit the tissue destructive effects of tissue disorders or diseases, are provided in international applications US92/01968 (W092/15323) ; US92/07358 (WO93/04692) and US92/07432 (WO93/05751) the disclosures of which are incorporated herein by reference. Morphogens, including the soluble morphogen complexes of this invention, are envisioned to have particular utility as part of therapies for regenerating lost or damaged bone, dentin, periodontal, liver, cardiac, lung and nerve tissue, as well as for protecting these tissues from the tissue destructive effects associated with an immunological response. The proteins also are anticipated to provide a tissue protective effect in the treatment of metabolic bone disorders, such as osteoporosis, osteomalacia and osteosarcoma; in the treatment of liver disorders, including cirrhosis, hepatitis, alcohol liver disease and hepatic encephalopathy; and in the treatment or prevention of ischemia reperfusion-associated tissue damage, particularly to nerve or cardiac tissue. Presented below are detailed descriptions of useful soluble morphogen complexes of this invention, as well as how to make and use them. I. Useful Soluble Morphogen Complexes - Protein Considerations Among the morphogens useful in this invention are proteins originally identified as osteogenic proteins, such as the OP-1, OP-2 and CBMP2 proteins, as well as amino acid sequence-related proteins such as DPP (from Drosophila), Vgl (from Xenopus), Vgr-1 (from mouse, see U.S. 5,011,691 to Oppermann et al.), GDF-1 (from mouse, see Lee (1991) PNAS 88:4250-4254), 60A protein (from Drosophila, Seq. ID No. 24, see Wharton et al. (1991) PNAS 13:9214-9218), and the recently identified OP-3. The members of this family, which are a subclass of the TGF-β super-family of proteins, share characteristic structural features, represented schematically in Fig. 1, as well as substantial amino acid sequence homology in their C-terminal domains, including a conserved seven cysteine structure. As illustrated in the figure, the proteins are translated as a precursor polypeptide sequence 10, having an N-terminal signal peptide sequence 12, (the "pre pro" region, indicated in the figure by cross-hatching), typically less than about 30 residues, followed by a "pro" region 14, indicated in the figure by stippling, and which is cleaved to yield the mature sequence 16. The mature sequence comprises both the conserved C-terminal seven cysteine domain 20, and an N-terminal sequence 18, referred to herein as an N-terminal extension, and which varies significantly in sequence between the various morphogens. Cysteines are represented in the figure by vertical hatched lines 22. The polypeptide chains dimerize and these di ers typically are stabilized by at least one interchain disulfide bond linking the two polypeptide chain subunits. The signal peptide is cleaved rapidly upon translation, at a cleavage site that can be predicted in a given sequence using the method of Von Heijne ((1986) Nucleic Acids Research 14:4683-4691.) The "pro" form of the protein subunit, 24, in Fig. 1, includes both the pro domain and the mature domain, peptide bonded together. Typically, this pro form is cleaved while the protein is still within the cell, and the pro domain remains noncovalently associated with the mature form of the subunit to form a soluble species that appears to be the primary form secreted from cultured mammalian cells. Typically, previous purification techniques utilized denaturing conditions that disassociated the complex. Other soluble forms of morphogens secreted from mammalian cells include dimers of the pro forms of these proteins, wherein the pro region is not cleaved from the mature domain, and "hemi-dimers", wherein one subunit comprises, a pro form of the polypeptide chain subunit and the other subunit comprises the cleaved mature form of the polypeptide chain subunit (including truncated forms thereof), preferably noncovalently associated with a cleaved pro domain. The isolated pro domain typically has a substantial hydrophobic character, as determined both by analysis of the sequence and by characterization of its properties in solution. The isolated pro regions alone typically are not significantly soluble in aqueous solutions, and require the presence of denaturants, e.g., detergents, urea, guanidine HC1, and the like, and/or one or more carrier proteins. Accordingly, without being limited to any given theory, the non-covalent association of the cleaved pro region with the mature morphogen dimeric species likely involves interaction of a hydrophobic portion of the pro region with a corresponding hydrophobic region on the dimeric species, the interaction of which effectively protects or "hides" an otherwise exposed hydrophobic region of the mature dimer from exposure to aqueous environments, enhancing the affinity of the mature dimer species for aqueous solutions. Morphogens comprise a subfamily of proteins within the TGF-β superfamily of structurally related proteins. Like the morphogens described herein, TGF-β also has a pro region which associates non-covalently with the mature TGF-β protein form. However, unlike the morphogens, the TGF-β pro region contains numerous cysteines and forms disulfide bonds with a specific binding protein. The TGF-βl pro domain also is phosphorylated at one or more mannose residues, while the morphogen pro regions typically are not. Useful pro domains include the full length pro regions described below, as well as various truncated forms hereof, particularly truncated forms cleaved at proteolytic Arg-Xaa-Xaa-Arg cleavage sites. For example, in OP-1, possible pro sequences include sequences defined by residues 30-292 (full length form); 48-292; and 158-292. Soluble OP-1 complex stability is enhanced when the pro region comprises the full length form rather than a truncated form, such as the 48-292 truncated form, in that residues 30-47 show sequence homology to the N-terminal portions of other morphogens, and are believed to have particular utility in enhancing complex stability for all morphogens. Accordingly, currently preferred pro sequences are those encoding the full length form of the pro region for a given morphogen (see below). Other pro sequences contemplated to have utility include biosynthetic pro sequences, particularly those that incorporate a sequence derived from the N-terminal portion of one or more morphogen pro sequences. Table I, below, describes the various preferred morphogens identified to date, including their nomenclature as used herein, the sequences defining the various regions of the subunit sequences, their Seq. ID references, and publication sources for their nucleic acid and amino acid sequences. The disclosure of these publications is incorporated herein by reference. The mature protein sequences defined are the longest anticipated forms of these sequences. As described above, shorter, truncated forms of these sequences also are contemplated. Preferably, truncated mature sequences include at least 10 amino acids of the N-terminal extension. Fig. 2 lists the N-terminal extensions for a number of the preferred morphogen sequences described below. Arg-Xaa-Xaa-Arg cleavage sites that may yield truncated sequences of the mature subunit form are boxed or underlined in the figure. TABLE I "OP-1" Refers generically to the group of morphogenically active proteins expressed from part or all of a DNA sequence encoding OP-1 protein, including allelic and species variants thereof, e.g., human OP-1 ("hOP-1"), or mouse OP-1 ("mOP-1".) The cDNA sequences and the amino acids encoding the full length proteins are provided in Seq. Id Nos. 1 and 2 (hOPl) and Seq. ID Nos. 3 and 4 (mOPl.) The mature proteins are defined by residues 293-431 (hOPl) and 292-430 (mOPl), wherein the conserved seven cysteine skeleton is defined by residues 330-431 and 329-430, respectively, and the N-terminal extensions are defined by residues 293-329 and 292-329, respectively. The "pro" regions of the proteins, cleaved to yield the mature, morphogenically active proteins, are defined essentially by residues 30-292 (hOPl) and residues 30-291 (mOPl). "OP-2" refers generically to the group of active proteins expressed from part or all of a DNA sequence encoding OP-2 protein, including allelic and species variants thereof, e.g., human OP-2 ("hOP-2") or mouse OP-2 ("mOP-2".) The full length proteins are provided in Seq. ID Nos. 5 and 6 (hOP2) and Seq. ID Nos. 7 and 8 (mOP2.) The mature proteins are defined essentially by residues 264-402 (hOP2) and 261-399 (mOP2), wherein the conserved seven cysteine skeleton is defined by residues 301-402 and 298-399, respectively, and the N-terminal extensions are defined by residues 264-300 and 261-297, respectively. The "pro" regions of the proteins, cleaved to yield the mature, morphogenically active proteins likely are defined essentially by residues 18-263 (hOP2) and residues 18-260 (mOP2). (Another cleavage site also occurs 21 residues upstream for both OP-2 proteins. ) "OP-3" refers generically to the group of active proteins expressed from part or all of a DNA sequence encoding OP-3 protein, including allelic and species variants thereof, e.g., mouse OP-3 ("mOP-3".) The full length protein is provided in Seq. ID No. 9. The mature protein is defined essentially by residues 261-399 or 264-399, wherein the conserved seven cysteine skeleton is defined by residues 298-399 and the N-terminal extension is defined by residues 264-297 or 261-297. The "pro" region of the protein, cleaved to yield the mature, morphogenically active proteins likely is defined essentially by residues 20-262. "BMP2/BMP4" refers to protein sequences encoded by the human BMP2 and BMP4 genes. The amino acid sequence for the full length proteins, referred to in the literature as BMP2A and BMP2B, or BMP2 and BMP4, appear in Seq. ID Nos. 10 and 11, respectively, and in Wozney, et al. (1988) Science 242:1528- 1534. The pro domain for BMP2 (BMP2A) likely includes residues 25-248 or 25-282; the mature protein, residues 249-396 or 283-396, of which residues 249-296/283-296 define the N-terminal extension and 295- 396 define the C-terminal domain. The pro domain for BMP4 (BMP2B) likely includes residues 25-256 or 25-292; the-mature protein, residues 257-408 or 293-408,of which 257-307/293-307 define the N- terminal extension, and 308-408 define the C-terminal domain. "DPP" refers to protein sequences encoded by the Drosophila DPP gene. The amino acid sequence for the full length protein, including the mature form and the pro region, appears in Seq.ID No. 12 and in Padgett, et al (1987) Nature 325: 81-84. The pro domain likely extends from the signal peptide cleavage site to residue 456; the mature protein likely is defined by residues 457-588, where residues 457- 586 define the N-terminal extension and 487-588 define the C-terminal domain. "Vgl" refers to protein sequences encoded by the Xenopus Vgl gene. The amino acid sequence for the full length protein, including the mature form and the pro region, appears in Seq.ID No. 13 and in Weeks (1987) Cell 5.: 861-867. The pro domain likely extends from the signal peptide cleavage site to residue 246; the mature protein likely is defined by residues 247-360, where residues 247-258 define the N-terminal extension, and residues 259-360 define the C-terminal domain. "Vgr-1" refers to protein sequences encoded by the murine Vgr-1 gene. The amino acid sequence for the full length protein, including the mature form and the pro region, appears in Seq. ID No. 14 and in Lyons, et al, (1989) PNAS 86: 4554-4558. The pro domain likely extends from the signal peptide cleavage site to residue 299; the mature protein likely is defined by residues 300-438, where residues 300-336 define the N-terminal extension and residues 337-438 define the C-terminus. "GDF-1" refers to protein sequences encoded by the human GDF-1 gene. The cDNA and encoded amino sequence for the full length protein is provided in Seq. ID. No. 15 and Lee (1991) PNAS 88:4250-4254. The pro domain likely extends from the signal peptide cleavage site to residue 214; the mature protein likely is defined by residues 215- 372, where residues 215-256 define the N- terminal extension and residues 257-372 define the C-terminus. "60A" refers to protein sequences encoded by the Drosophila 60A gene. The amino acid sequence for the full length protein appears in Seq. ID No. 16 and in Wharton et al. (1991) PNAS 8i8_:9214-9218) The pro domain likely extends from the signal peptide cleavage site to residue 324; the mature protein likely is defined by residues 325-455, wherein residues 325-353 define the N-terminal extension and residues 354-455 define the C-terminus. "BMP3" refers to protein sequences encoded by the human BMP3 gene. The amino acid sequence for the full length protein, including the mature form and the pro region, appears in Seq.ID No. 17 and in Wozney et al. (1988) Science 242: 1528-1534. The pro domain likely extends from the signal peptide cleavage site to residue 290; the mature protein likely is defined by residues 291- 472, wherein residues 291-370 define the N-terminal extension and residues 371-472 define the C-terminus. "BMP5" refers to protein sequences encoded by the human BMP5 gene. The amino acid sequence for the full length protein, including the mature form and the pro region, appears in Seq.ID No. 18 and in Celeste, et al. (1990) PNAS 87: 9843-9847. The pro domain likely extends from the signal peptide cleavage site to residue 316; the mature protein likely is defined by residues 317-454, where residues 317-352 define the N-terminus and residues 352-454 define the C-terminus. "BMP6" refers to protein sequences encoded by the human BMP6 gene. The amino acid sequence for the full length protein, including the mature form and the pro region, appears in Seq. ID No. 16 and in Celeste, et al. (1990) PNAS 87: 9843-5847. The pro domain likely includes extends from the signal peptide cleavage site to residue 374; the mature sequence likely includes residues 375-513, where residues 375-411 define the N-terminus and residues 412-513 define the C-terminus. Note that the OP-2 and OP-3 proteins have an additional cysteine residue in the C-terminal region (e.g., see residue 338 in these sequences), in addition to the conserved cysteine skeleton in common with the other proteins in this family. The GDF-1 protein has a four amino acid insert within the conserved skeleton ("Gly-Gly-Pro-Pro") but this insert likely does not interfere with the relationship of the cysteines in the folded structure. In addition, the CBMP2 proteins are missing one amino acid residue within the cysteine skeleton. The dimeric morphogen species are inactive when reduced, but are active as oxidized homodimers and when oxidized in combination with other morphogens of this invention. Thus, as defined herein, a morphogen useful in a soluble morphogen complex is a dimeric protein comprising a pair of polypeptide chains, wherein each polypeptide chain has less than 200 amino acids and comprises at least the C-terminal six, preferably seven cysteine skeleton defined by residues 335-431 of Seq. ID No. 1, including functionally equivalent arrangements of these cysteines (e.g., amino acid insertions or deletions which alter the linear arrangement of the cysteines in the sequence but not their relationship in the folded structure), such that, when the polypeptide chains are folded, the dimeric protein species comprising the pair of polypeptide chains has the appropriate three-dimensional structure, including the appropriate intra- or inter-chain disulfide bonds such that the protein is capable of acting as a morphogen as defined herein. The solubility of these structures is improved when the mature dimeric form of a morphogen, in accordance with the invention, is complexed with at least one, and preferably two, pro domains. Various generic sequences (Generic Sequence 1-6) defining preferred C-terminal sequences useful in the soluble morphogens of this invention are described in USSN 07/923,780, incorporated herein above by reference. Two currently preferred generic sequences are described below. Generic Sequence 7 (Seq. ID No. 20) and Generic Sequence 8 (Seq. ID No. 21) disclosed below, accommodate the homologies shared among preferred morphogen protein family members identified to date, including OP-1, OP-2, OP-3, CBMP2A, CBMP2B, BMP3, 60A, DPP, Vgl, BMP5, BMP6, Vrg-1, and GDF-1. The amino acid sequences for these proteins are described herein (see Sequence Listing) and/or in the art, as well as in PCT publication US 92/07358, (WO93/04692), for example. The generic sequences include both the amino acid identity shared by these sequences in the C-terminal domain, defined by the six and seven cysteine skeletons (Generic Sequences 7 and 8, respectively), as well as alternative residues for the variable positions within the sequence. The generic sequences allow for an additional cysteine at position 41 (Generic Sequence 7) or position 46 (Generic Sequence 8), providing an appropriate cysteine skeleton where inter- or intramolecular disulfide bonds can form, and containing certain critical amino acids which influence the tertiary structure of the proteins. Generic Sequence 7 Leu Xaa Xaa Xaa Phe 1 5 Xaa Xaa Xaa Gly Trp Xaa Xaa Xaa Xaa 10 Xaa Xaa Pro Xaa Xaa Xaa Xaa Ala 15 20 Xaa Tyr Cys Xaa Gly Xaa Cys Xaa 25 30 Xaa Pro Xaa Xaa Xaa Xaa Xaa 35 Xaa Xaa Xaa Asn His Ala Xaa Xaa 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys 55 60 Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa 65 Xaa Xaa Xaa Leu Xaa Xaa Xaa 70 75 Xaa Xaa Xaa Xaa Val Xaa Leu Xaa 80 Xaa Xaa Xaa Xaa Met Xaa Val Xaa 85 90 Xaa Cys Xaa Cys Xaa 95 wherein each Xaa is independently selected from a group of one or more specified amino acids defined as follows: "Res." means "residue" and Xaa at res.2 = (Tyr or Lys); Xaa at res.3 = Val or lie); Xaa at res.4 = (Ser, Asp or Glu); Xaa at res.6 = (Arg, Gin, Ser, Lys or Ala); Xaa at res.7 = (Asp or Glu); Xaa at res.8 = (Leu, Val or lie); Xaa at res.11 = (Gin, Leu, Asp, His, Asn or Ser); Xaa at res.12 = (Asp, Arg, Asn or Glu); Xaa at res. 13 = (Trp or Ser); Xaa at res.14 = (lie or Val); Xaa at res.15 = (lie or Val); Xaa at res.16 (Ala or Ser); Xaa at res.18 = (Glu, Gin, Leu, Lys, Pro or Arg); Xaa at res.19 = (Gly or Ser); Xaa at res.20 = (Tyr or Phe); Xaa at res.21 = (Ala, Ser, Asp, Met, His, Gin, Leu or Gly); Xaa at res.23 = (Tyr, Asn or Phe); Xaa at res.26 = (Glu, His, Tyr, Asp, Gin, Ala or Ser); Xaa at res.28 = (Glu, Lys, Asp, Gin or Ala); Xaa at res.30 = (Ala, Ser, Pro, Gin, lie or Asn); Xaa at res.31 = (Phe, Leu or Tyr); Xaa at res.33 = (Leu, Val or Met); Xaa at res.34 = (Asn, Asp, Ala, Thr or Pro); Xaa at res.35 = (Ser, Asp, Glu, Leu, Ala or Lys); Xaa at res.36 = (Tyr, Cys, His, Ser or lie); Xaa at res.37 = (Met, Phe, Gly or Leu); Xaa at res.38 = (Asn, Ser or Lys); Xaa at res.39 = (Ala, Ser, Gly or Pro); Xaa at res.40 = (Thr, Leu or Ser); Xaa at res.44 = (lie, Val or Thr); Xaa at res.45 = (Val, Leu, Met or lie); Xaa at res.46 = (Gin or Arg); Xaa at res.47 = (Thr, Ala or Ser); Xaa at res.48 = (Leu or lie); Xaa at res.49 = (Val or Met); Xaa at res.50 = (His, Asn or Arg); Xaa at res.51 = (Phe, Leu, Asn, Ser, Ala or Val); Xaa at res.52 = (He, Met, Asn, Ala, Val, Gly or Leu); Xaa at res.53 = (Asn, Lys, Ala, Glu, Gly or Phe); Xaa at res.54 = (Pro, Ser or Val); Xaa at res.55 = (Glu, Asp, Asn, Gly, Val, Pro or Lys); Xaa at res.56 = (Thr, Ala, Val, Lys, Asp, Tyr, Ser, Gly, He or His); Xaa at res.57 = (Val, Ala or He); Xaa at res.58 - (Pro or Asp); Xaa at res.59 = (Lys, Leu or Glu); Xaa at res.60 = (Pro, Val or Ala); Xaa at res.63 = (Ala or Val); Xaa at res.65 = (Thr, Ala or Glu); Xaa at res.66 = (Gin, Lys, Arg or Glu); Xaa at res.67 = (Leu, Met or Val); Xaa at res.68 = (Asn, Ser, Asp or Gly); Xaa at res.69 = (Ala, Pro or Ser); Xaa at res.70 = (He, Thr, Val or Leu); Xaa at res.71 = (Ser, Ala or Pro); Xaa at res.72 = (Val, Leu, Met or He); Xaa at res.74 = (Tyr or Phe); Xaa at res.75 = (Phe, Tyr, Leu or His); Xaa at res.76 = (Asp, Asn or Leu); Xaa at res.77 = (Asp, Glu, Asn, Arg or Ser); Xaa at res.78 = (Ser, Gin, Asn, Tyr or Asp); Xaa at res.79 = (Ser, Asn, Asp, Glu or Lys); Xaa at res.80 = (Asn, Thr or Lys); Xaa at res.82 = (He, Val or Asn); Xaa at res.84 = (Lys or Arg); Xaa at res.85 = (Lys, Asn, Gin, His, Arg or Val); Xaa at res.86 = (Tyr, Glu or His); Xaa at res.87 = (Arg, Gin, Glu or Pro); Xaa at res.88 = (Asn, Glu, Trp or Asp); Xaa at res.90 = (Val, Thr, Ala or He); Xaa at res.92 = (Arg, Lys, Val, Asp, Gin or Glu); Xaa at res.93 = (Ala, Gly, Glu or Ser); Xaa at res.95 = (Gly or Ala) and Xaa at res.97 = (His or Arg). As described above. Generic Sequence 8 (Seq. ID No. 21) includes all of Generic Sequence 7 and in addition includes the following sequence at its N-terminus: Cys Xaa Xaa Xaa Xaa 1 5 Accordingly, beginning with residue 7, each "Xaa" in Generic Seq. 8 is a specified amino acid defined as for Generic Seq. 7, with the distinction that each residue number described for Generic Sequence 7 is shifted by five in Generic Seq. 8. Thus, "Xaa at res.2 =(Tyr or Lys)" in Gen. Seq. 7 refers to Xaa at res. 7 in Generic Seq. 8. In Generic Seq. 8, Xaa at res.2 = (Lys, Arg, Ala or Gin); Xaa at res.3 = (Lys, Arg or Met); Xaa at res.4 = (His, Arg or Gin); and Xaa at res.5 = (Glu, Ser, His, Gly, Arg, Pro, Thr, or Tyr). Accordingly, other useful sequences defining preferred C-terminal sequences are those sharing at least 70% amino acid sequence homology or "similarity", and preferably 80% homology or similarity with any of the sequences incorporated into Generic Seq. 7 and 8 above. These are anticipated to include allelic, species, chimeric and other sequence variants, (e.g., including "muteins" or "mutant proteins"), whether naturally-occurring or biosynthetically produced, as well as novel members of this morphogenic family of proteins. As used herein, "amino acid sequence homology" is understood to mean amino acid sequence similarity, and homologous sequences share identical or similar amino acids, where similar amino acids are conserved amino acids as defined by Dayoff et al.. Atlas of Protein Sequence and Structure; vol.5, Suppl.3, pp.345-362 (M.O. Dayoff, ed. , Nat'l BioMed. Research Fdn., Washington D.C. 1978.) Thus, a candidate sequence sharing 70% amino acid homology with a reference sequence requires that, following alignment of the candidate sequence with the reference sequence, 70% of the amino acids in the candidate sequence are identical to the corresponding amino acid in the reference sequence, or constitute a conserved amino acid change thereto. "Amino acid sequence identity" is understood to require identical amino acids between two aligned sequences. Thus, a candidate sequence sharing 60% amino acid identity with a reference sequence requires that, following alignment of the candidate sequence with the reference sequence, 60% of the amino acids in the candidate sequence are identical to the corresponding amino acid in the reference sequence. As used herein, all homologies and identities calculated use OP-1 as the reference sequence. Also as used herein, sequences are aligned for homology and identity calculations using the method of Needleman et al. (1970) J.Mol. Biol. 48:443-453 and identities calculated by the Align program (DNAstar, Inc.) In all cases, internal gaps and amino acid insertions in the candidate sequence as aligned are ignored when making the homology/identity calculation. Also as used herein, "sequence variant" is understood to mean an amino acid sequence variant form of the morphogen protein, wherein the amino acid change or changes in the sequence do not alter significantly the morphogenic activity (e.g., tissue regeneration activity) of the protein, and the variant molecule performs substantially the same function in substantially the same way as the naturally-occurring form of the molecule. Sequence variants may include single or multiple amino acid changes, and are intended to include chimeric sequences as described below. The variants may be naturally-occurring or may be biosynthetically induced by using standard recombinant DNA techniques or chemical protein synthesis methodologies. The currently most preferred protein sequences useful in soluble morphogen complexes in this invention include those having greater than 60% identity, preferably greater than 65% identity, with the amino acid sequence defining the conserved six cysteine skeleton of hOPl (e.g., residues 335-431 of Seq. ID No. 5). These most preferred sequences include both allelic and species variants of the OP-1 and OP-2 proteins, including the Drosophila 60A protein. Accordingly, in another preferred aspect of the invention, useful morphogens include active proteins comprising species of polypeptide chains having the generic amino acid sequence herein referred to as "OPX", which accommodates the homologies between the various identified species of OP1 and OP2 (Seq. ID No. 22). In still another preferred aspect of the invention, useful morphogens include active proteins comprising amino acid sequences encoded by nucleic acids that hydridize to DNA or RNA sequences encoding the conserved C-terminal cysteine domain of OP1 or OP2, e.g., defined by nucleotides 1036-1341 and nucleotides 1390-1695 of Seq. ID Nos. 1 and 5, respectively, under stringent hybridization conditions. As used herein, stringent hybridization conditions are defined as hybridization in 40% formamide, 5 X SSPE, 5 X Denhardt's Solution, and 0.1% SDS at 37°C overnight, and washing in 0.1 X SSPE, 0.1% SDS at 50°C. Similarly, in another preferred aspect of the invention, useful pro region peptides include polypeptide chains comprising amino acid sequences encoded by nucleic acids that hybridize to DNA or RNA sequences encoding at least the N-terminal 18 amino acids of the pro region sequences for any of the sequences listed in Seq. ID Nos. 1-19, under stringent hybridization conditions. Most preferably, the peptides are encoded by nucleic acids that hybridize to the DNA or RNA sequences encoding at least the N-terminal 18 amino acids of the pro region sequences for OP1 or OP2, e.g., nucleotides 136-192 and nucleotides 152-211 of Seq. ID Nos. 1 and 5, respectively. Useful N-terminal extension sequences are listed in Fig. 2 for use with the C-terminal domains described above. Also as described above, the full length N- terminal extensions, or truncated forms thereof, may be used in preferred dimeric species. The mature dimeric species may be produced from intact DNAs, or truncated forms thereof. It also is envisioned as an embodiment of the invention that chimeric morphogen sequences can be used. Thus, DNAs encoding chimeric morphogens may be constructed using part or all of the N-terminal extension from one morphogen and a C-terminal domain derived from one or more other morphogens. These chimeric proteins may be synthesized using standard recombinant DNA methodology and/or automated chemical nucleic acid synthesis methodology well described in the art. Other chimeric morphogens include soluble morphogen complexes where the pro domain is encoded from a DNA sequence corresponding to one or more morphogen pro sequences, and part or all of the mature domain is encoded by DNA derived from one or more other, different morphogens. These soluble chimerics may be produced from a single synthetic DNA as described below, or, alternatively, may be formulated in vitro from isolated components also as described herein below. Finally, the morphogen pro domains and/or mature form N-terminal extensions themselves may be useful as tissue targeting sequences. As described above, the morphogen family members share significant sequence homology in their C-terminal active domains. By contrast, the sequences diverge significantly in the sequences which define the pro domain and the N-terminal 39 amino acids of the mature protein. Accordingly, the pro domain and/or N-terminal extension sequence may be morphogen-specific. Accordingly, part or all of these morphogen-specific sequences may serve as tissue targeting sequences for the morphogens described herein. For example, the N-terminal extension and/or pro domains may interact specifically with one or more molecules at the target tissue to direct the morphogen associated with the pro domain to that tissue. Thus, for example, the morphogen-specific sequences of OP-1, BMP2 or BMP4, all of which proteins are found naturally associated with bone tissue (see, for example, US Pat. No. 5,011,691) may be particularly useful sequences when the morphogen complex is to be targeted to bone. Similarly, BMP6 (or Vgr-1) specific sequences may be used when targeting to lung tissue is desired. Alternatively, the morphogen-specific sequences of GDF-1 may be used to target soluble morphogen complexes to nerve tissue, particularly brain tissue, where GDF-1 appears to be primarily expressed (see, for example, Lee, PNAS, £58:4250-4254 (1991), incorporated herein by reference) . II. Recombinant Production of Soluble Morphogen Complexes Soluble morphogen complexes can be produced from eukaryotic host cells, preferably mammalian cells, using standard recombinant expression techniques. An exemplary protocol currently preferred, is provided below, using a particular vector construct and Chinese hamster ovary (CHO) cell line. Those skilled in the art will appreciate that other expression systems are contemplated to be useful, including other vectors and other cell systems, and the invention is not intended to be limited to soluble morphogenic protein complexes produced only by the method detailed hereinbelow. Similar results to those described herein have been observed using recombinant expression systems developed for COS and BSC cells. Morphogen DNA encoding the precursor sequence is subcloned into an insertion site of a suitable, commercially available pUC-type vector (e.g., pUC-19, ATCC #37254, Rockville, MD), along with a suitable promoter/enhancer sequences and 3' termination sequences. Useful DNA sequences include the published sequences encoding these proteins, and/or synthetic constructs. Currently preferred promoter/enhancer sequences are the CMV promoter (human cytomegalovirus major intermediate - early promoter) and the mouse mammary tumor virus promoter (mMTV) boosted by the rous sarcoma virus LTR enhancer sequence (e.g., from Clontech, Inc., Palo Alto). Expression also may be further enhanced using transactivating enhancer sequences. The plasmid also contains DHFR as an amplifiable marker, under SV40 early promoter control (ATCC #37148). Transfection, cell culturing, gene amplification and protein expression conditions are standard conditions, well known in the art, such as are described, for example in Ausubel et al., ed.. Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989). Briefly, transfected cells are cultured in medium containing 0.1-0.5% dialyzed fetal calf serum (FCS) and stably transfected high expression cell lines are obtained by subcloning and evaluated by standard Western or Northern blot. Southern blots also are used to assess the state of integrated sequences and the extent of their copy number amplification. A currently preferred expression vector contains the DHFR gene, under SV40 early promoter control, as both a selection marker and as an inducible gene amplifier. The DNA sequence for DHFR is well characterized in the art, and is available commercially. For example, a suitable vector may be generated from pMAM-neo (Clontech, Inc., Palo Alto, CA) by replacing the neo gene (BamHI digest) with an Sphl- BamHI, or a PvuII-BamHI fragment from pSV5-DHFR (ATCC #37148), which contains the DHFR gene under SV40 early promoter control. A BamHI site can be engineered at the SphI or PvuII site using standard techniques (e.g., by linker insertion or site-directed mutagenesis) to allow insertion of the fragment into the vector backbone. The morphogen DNA can be inserted into the polylinker site downstream of the MMTV-LTR sequence (mouse mammary tumor virus LTR) . The CMV promoter sequence then may be inserted into the expression vector (e.g., from pCDM8, Invitrogen, Inc.) The SV40 early promoter, which drives DHFR expression, preferably is modified in these vectors to reduce the level of DHFR mRNA produced. The currently preferred mammalian cell line is a CHO Chinese hamster ovary, cell line, and the preferred procedure for establishing a stable morphogen production cell line with high expression levels comprises transfecting a stable CHO cell line, preferably CHO-DXB11, with the expression vector described above, isolating clones with highjnorphogen expression levels, and subjecting these clones to cycles of subcloning using a limited dilution method described below to obtain a population of high expression clones. Subcloning preferably is performed in the absence of MTX to identify stable high expression clones which do not require addition of MTX to the growth media for morphogen production. In the subcloning protocol cells are seeded on ten 100mm petri dishes at a cell density of either 50 or 100 cells per plate, with or preferably without MTX in the culture media. After 14 days of growth, clones are isolated using cloning cylinders and standard procedures, and cultured in 24-well plates. Clones then are screened for morphogen expression by Western immunoblots using standard procedures, and morphogen expression levels compared to parental lines. Cell line stability of high expression subclones then is determined by monitoring morphogen expression levels over multiple cell passages (e.g., four or five passages) . III. Isolation of Soluble morphogen complex from conditioned media or body fluid Morphogens are expressed from mammalian cells as soluble complexes. Typically, however the complex is disassociated during purification, generally by exposure to denaturants often added to the purification solutions, such as detergents, alcohols, organic solvents, chaotropic agents and compounds added to reduce the pH of the solution. Provided below is a currently preferred protocol for purifying the soluble proteins from conditioned media (or, optionally, a body fluid such as serum, cerebro-spinal or peritoneal fluid), under non-denaturing conditions. The method is rapid, reproducible and yields isolated soluble morphogen complexes in substantially pure form. Soluble morphogen complexes can be isolated from conditioned media using a simple, three step chromatographic protocol performed in the absence of denaturants. The protocol involves running the media (or body fluid) over an affinity column, followed by ion exchange and gel filtration chromatographies. The affinity column described below is a Zn-IMAC column. The present protocol has general applicability to the purification of a variety of morphogens, all of which are anticipated to be isolatable using only minor modifications of the protocol described below. An alternative protocol also envisioned to have utility an immunoaffinity column, created using standard procedures and, for example, using antibody specific for a given morphogen pro domain (complexed, for example, to a protein A-conjugated Sepharose column. ) Protocols for developing immunoaffinity columns are well described in the art, (see, for example. Guide to Protein Purification, M. Deutscher, ed.. Academic Press, San Diego, 1990, particularly sections VII and XI.) In this experiment OP-1 was expressed in CHO cells as described above. The CHO cell conditioned media containing 0.5% FBS was initially purified using Immobilized Metal-Ion Affinity Chromatography (IMAC). The soluble OP-1 complex from conditioned media binds very selectively to the Zn-IMAC resin and a high concentration of imidazole (50 mM imidazole, pH 8.0) is required for the effective elution of the bound complex. The Zn-IMAC step separates the soluble OP-1 from the bulk of the contaminating serum proteins that elute in the flow through and 35 mM imidazole wash fractions. The Zn-IMAC purified soluble OP-1 is next applied to an S-Sepharose cation-exchange column equilibrated in 20 mM NaP0 4 (pH 7.0) with 50 mM NaCl. This S-Sepharose step serves to further purify and concentrate the soluble OP-1 complex in preparation for the following gel filtration step. The protein was applied to a Sephacryl S-200HR column equilibrated in TBS. Using substantially the same protocol, soluble morphogens also may be isolated from one or more body fluids, including serum, cerebro-spinal fluid or peritoneal fluid. IMAC was performed using Chelating-Sepharose (Pharmacia) that had been charged with three column volumes of 0.2 M ZnSO.. The conditioned media was titrated to pH 7.0 and applied directly to the ZN-IMAC resin equilibrated in 20 mM HEPES (pH 7.0) with 500 mM NaCl. The Zn-IMAC resin was loaded with 80 mL of starting conditioned media per mL of resin. After loading the column was washed with equilibration buffer and most of the contaminating proteins were eluted with 35 mM imidazole (pH 7.0) in equilibration buffer. The soluble OP-1 complex is then eluted with 50 mM imidazole (pH 8.0) in 20 mM HEPES and 500 mM NaCl. The 50 mM imidazole eluate containing the soluble OP-1 complex was diluted with nine volumes of 20 mM NaPO. (pH 7.0) and applied to an S-Sepharose (Pharmacia) column equilibrated in 20 mM NaPO. (pH 7.0) with 50 mM NaCl. The S-Sepharose resin was loaded with an equivalent of 800 mL of starting conditioned media per mL of resin. After loading the S-Sepharose column was washed with equilibration buffer and eluted with 100 mM NaCl followed by 300 mM and 500 mM NaCl in 20 mM NaP0 4 (pH 7.0). The 300 mM NaCl pool was further purified using gel filtration chromatography. Fifty mis of the 300 mm NaCl eluate was applied to a 5.0 X 90 cm Sephacryl S-200HR (Pharmacia) equilibrated in Tris buffered saline (TBS), 50 mM Tris, 150 mM NaCl (pH 7.4). The column was eluted at a flow rate of 5 mL/minute collecting 10 mL fractions. The apparent molecular of the soluble OP-1 was determined by comparison to protein molecular weight standards (alcohol dehydrogenase (ADH, 150 kDa), bovine serum albumin (BSA, 68 kDa), carbonic anhydrase (CA, 30 kDa) and cytochrome C (cyt C, 12.5 kDa). (see Fig. 3) The purity of the S-200 column fractions was determined by separation on standard 15% polyacrylamide SDS gels stained with coomassie blue. The identity of the mature OP-1 and the pro-domain was determined by N-terminal sequence analysis after separation of the mature OP-1 from the pro-domain using standard reverse phase C18 HPLC. Figure 3 shows the absorbance profile at- 280 nm. The soluble OP-1 complex elutes with an apparent molecular weight of 110 kDa. This agrees well with the predicted composition of the soluble OP-1 complex with one mature OP-1 dimer (35-36 kDa) associated with two pro-domains (39 kDa each). Purity of the final complex can be verified by running the appropriate fraction in a reduced 15% polyacrylamide gel. The complex components can be verified by running the complex-containing fraction from the S-200 or S- 200HR columns over a reverse phase C18 HPLC column and eluting in an acetonitrile gradient (in 0.1% TFA), using standard procedures. The complex is dissociated by this step, and the pro domain and mature species elute as separate species. These separate species then can be subjected to N-terminal sequencing using standard procedures (see, for example. Guide to Protein Purification, M. Deutscher, ed.. Academic Press, San Diego, 1990, particularly pp. 602-613), and the identity of the isolated 36kD, 39kDa proteins confirmed as mature morphogen and isolated, cleaved pro domain, respectively. N-terminal sequencing of the isolated pro domain from mammalian cell produced OP-1 revealed 2 forms of the pro region, the intact form (beginning at residue 30 of Seq. ID No. 1) and a truncated form, (beginning at residue 48 of Seq. ID No. 1.) N-terminal sequencing of the polypeptide subunit of the isolated mature species reveals a range of N- termini for the mature sequence, beginning at residues 293, 300, 313, 315, 316, and 318, of Seq. ID No. 1, all of which are active as demonstrated by the standard bone induction assay. V. In Vitro Soluble Morphogen Complex Formation As an alternative to purifying soluble complexes from culture media or a body fluid, soluble complexes may be formulated from purified pro domains and mature dimeric species. Successful complex formation apparently requires association of the components under denaturing conditions sufficient to relax the folded structure of these molecules, without affecting disulfide bonds. Preferably, the denaturing conditions mimic the environment of an intracellular vesicle sufficiently such that the cleaved pro domain has an opportunity to associate with the mature dimeric species under relaxed folding conditions. The concentration of denaturant in the solution then is decreased in a controlled, preferably step-wise manner, so as to allow proper refolding of the dimer and pro regions while maintaining the association of the pro domain with the dimer. Useful denaturants include 4-6M urea or guanidine hydrochloride (GuHCl), in buffered solutions of pH 4-10, preferably pH 6-8. The soluble complex then is formed by controlled dialysis or dilution into a solution having a final denaturant concentration of less than 0.1-2M urea or GuHCl, preferably 1-2 M urea of GuHCl, which then preferably can be diluted into a physiological buffer. Protein purification/renaturing procedures and considerations are well described in the art, and details for developing a suitable renaturing protocol readily can be determined by one having ordinary skill in the art. One useful text one the subject is Guide to Protein Purification, M. Deutscher, ed.. Academic Press, San Diego, 1990, particularly section V. Complex formation also may be aided by addition of one or more chaperone proteins. VI. Stability of Soluble Morphogen Complexes The stability of the highly purified soluble morphogen complex in a physiological buffer, e.g., tris-buffered saline (TBS) and phosphate-buffered saline (PBS), can be enhanced by any of a number of means. Currently preferred is by means of a pro region that comprises at least the first 18 amino acids of the pro sequence (e.g., residues 30-47 of Seq. ID NO. 1 for OP-1), and preferably is the full length pro region. Residues 30-47 show sequence homology to the N-terminal portion of other morphogens and are believed to have particular utility in enhancing complex stability for all morphogens. Other useful means for enhancing the stability of soluble morphogen complexes include three classes of additives. These additives include basic amino acids (e.g., L-arginine, lysine and betaine); nonionic detergents (e.g., Tween 80 or Nonldet P-120); and carrier proteins (e.g., serum albumin and casein). Useful concentrations of these additives include 1-100 mM, preferably 10-70 mM, including 50 mM, basic amino acid;, 0.01-1.0%, preferably 0.05-0.2%, including 0.1% (v/v) nonionic detergent;, and 0.01-1.0%, preferably 0.05-0.2%, including 0.1% (w/v) carrier protein. VII. Activity of Soluble Morphogen Complex Association of the pro domain with the mature dimeric species does not interfere with the morphogenic activity of the protein in vivo as demonstrated by different activity assays. Specifically, soluble OP-1 complex provided in a standard rat osteopenia model induces significant increase in bone growth and osteocalcin production (see Table II, below), in a manner analogous to the results obtained using mature morphogen. The assay is analogous to the osteoporosis model described in international application US92/07432 (WO93/05751) , but uses aged female rats rather than ovariectomized animals. Briefly, young or aged female rats (Charles River Labs, 115-145, and 335-460g body weight, respectively) were dosed daily for 7 days by intravenous tail injection, with either 20 μg/Kg body weight soluble OP-1, or 100 μg/Kg body weight soluble OP-1. Control groups of young and aged female rats were dosed only with tris-buffered saline (TBS). Water and food were provided to all animals ad libitum. After 14 days, animals were sacrificed, and new bone growth measured by standard histometric procedures. Osteocalcin concentrations in serum also were measured. No detrimental effects of morphogen administration were detected as determined by changes in animal body or organ weight or by hematology profiles. Aged female, 7.68 + 0.63** 22.24 + 2.28** 20μg/Kg sol. OP-1 Aged female, 9.82 + 3.31* 20.87 + 6.14* lOOμg/Kg sol. OP-1 *P < 0.05 **P < 0.01 Similar experiments performed using soluble OP-1 complex in the osteoporosis model described in WO93/05751 using ovariectomized rats also show no detrimental effect using the complex form. Both mature and soluble morphogen also can induce CAM (cell adhesion molecule) expression, as demonstrated below. Briefly, induction of N-CAM isoforms (N-CAM-180, N-CAM-140 and N-CAM-120) can be monitored by reaction with the commercially available antibody mAb H28.123 (Sigma Co., St. Louis) and available antibody mAb H28.123 (Sigma Co., St. Louis) and standard Western blot analysis (see, for example. Molecular Cloning, A Laboratory Manual, Sambrook et al. eds. Cold Spring Harbor Press, New York, 1989, particularly Section 18). Incubation of a growing culture of transformed cells of neuronal origin, NG108-15 eels (ATCC, Rockville, MD) with either mature morphogen dimers or soluble morphogen complexes (10-100 ng/ml, preferably at least 40 ng/ml) induces a redifferentiation of these cells back to a morphology characteristic of untransformed neurons, including specific induction and/or enhanced expression of all 3 N-CAM isoforms. In the experiment, cells were subcultured on poly-L-lysine coated 6-well plates and grown in chemically defined medium for 2 days before the experiment. Fresh aliquots of morphogen were added (2.5μl) daily. VIII. Antibody Production Provided below are standard protocols for polycolonal and monoclonal antibody production. For antibodies which recognize the soluble complex only, preferably the isolated pro region is used as the antigen; where antibodies specific to the mature protein are desired, the antigen preferably comprises at least the C-terminal domain or the intact mature sequence. Polyclonal antibody may be prepared as follows. Each rabbit is given a primary immunization of 100 ug/500 μl of antigen, in 0.1% SDS mixed with 500 μl Complete Freund's Adjuvant. The antigen is injected subcutaneously at multiple sites on the back and flanks of the animal. The rabbit is boosted after a month in the same manner using incomplete Freund's Adjuvant. Test bleeds are taken from the ear vein seven days later. Two additional boosts and test bleeds are performed at monthly intervals until antibody against the morphogen antigen is detected in the serum using an ELISA assay. Then, the rabbit is boosted monthly with 100 μg of antigen and bled (15 ml per bleed) at days seven and ten after boosting. Monoclonal antibody specific for a given morphogen may be prepared as follows. A mouse is given two injections of the morphogen antigen. The protein or protein fragment preferably is recombinantly produced. The first injection contains lOOμg of antigen in complete Freund's adjuvant and is given subcutaneously. The second injection contains 50 μg of antigen in incomplete adjuvant and is given intraperitoneally. The mouse then receives a total of 230 μg of OP-3 in four intraperitoneal injections at various times over an eight month period. One week prior to fusion, the mouse is boosted intraperitoneally with antigen (e.g., 100 μg) and may be additionally boosted with a peptide fragment conjugated to bovine serum albumin with a suitable crosslinking agent. This boost can be repeated five days (IP), four days (IP) / three days (IP) and one day (IV) prior to fusion. The mouse spleen cells then are fused to commercially available myeloma cells at a ratio of 1:1 using PEG 1500 (Boeringer Mannheim, Germany), and the fused cells plated and screened for mature or soluble morphogen- specific antibodies using the appropriate portion of the morphogen sequence as antigen. The cell fusion and monoclonal screening steps readily are performed according to standard procedures well described in standard texts widely available in the art. Using these standard procedures, anti-pro domain antisera was prepared from rabbits using the isolated pro domain from OP-1 as the antigen, and monoclonal antibody ("mAb") to the mature domain was produced in mice, using an E. coli-produced truncated form of OP-1 as antigen. Standard Western blot analysis performed under reducing conditions demonstrates that the anti-pro domain antisera ("anti-pro") is specific for the pro domain only, while the mAb to mature OP-1 ("anti-mature OP-1") is specific for the dimer subunits, that the two antibodies do not cross-react, and that the antibodies and can be used to distinguish between soluble and mature protein forms in a sample, e.g., of conditioned media or serum. A tabular representation of the Western blot results is in Table III below, where reactivity of mAb to mature OP-1 is indicated by "yy", and reactivity of the anti-pro antisera is indicated by TABLE III Purified Purified Conditioned Isolated Dimer Antibody Sol OPl CHO Cell Media Pro Domain Subunits "anti-pro" xx xx xx "anti- yy yy yy mature OP-1" IX. Immunoassays The ability to detect morphogens in solution and to distinguish between soluble and mature dimeric morphogen forms provides a valuable tool for-diagnostic assays, allowing one to monitor the level and type of morphogen free in the body, e.g., in serum and other body fluids, as well as to develop diagnostic and other tissue evaluating kits. For example, OP-1 is an intimate participant in normal bone growth and resorption. Thus, soluble OP-1 is expected to be detected at higher concentrations in individuals experiencing high bone turnover, such as children, and at substantially lower levels in individuals with abnormally low rates of bone turnover, such as patients with osteoporosis, osteosarcoma, Paget's disease and the like. Monitoring the level of OP-1, or other bone targeted morphogens such as BMP2 and BMP4, in serum thus provides a means for evaluating the status of bone tissue in an individual, as well as a means for monitoring the efficacy of a treatment to regenerate damaged or lost bone tissue. Similarly, monitoring the level of endogenous GDF-1, can provide diagnostic information on the health of nerve tissue, particularly brain tissue. Moreover, following this disclosure one can distinguish between the level of soluble and mature forms in solution. A currently preferred detection means for evaluating the level of morphogen in a body fluid comprises an immunoassay utilizing an antibody or other suitable binding protein capable of reacting specifically with a morphogen and being detected as part of a complex with the morphogen. Immunoassays may be performed using standard techniques known in the art and antibodies raised against a morphogen and specific for that morphogen. Antibodies which recognize a morphogen protein form of interest may be generated as described herein and these antibodies then used to monitor endogenous levels of protein in a body fluid, such as serum, whole blood or peritoneal fluid. To monitor endogenous concentrations of soluble morphogen, the antibody chosen preferably has binding specificity for the soluble form e.g., has specificity for the pro domain. Such antibodies may be generated by using the pro domain or a portion thereof as the antigen, essentially as described herein. A suitable pro domain for use as an antigen may be obtained by isolating the soluble complex and then separating the noncovalently associated pro domain from the mature domain using standard procedures, e.g., by passing the complex over an HPLC column, as described above or by separation by gel electrophoresis. Alternatively, the pro form of the protein in its monomeric form may be used as the antigen and the candidate antibodies screened by Western blot or other standard immunoassay for those which recognize the pro domain of the soluble form of the protein of interest, but not the mature form, also as described above. Monomeric pro forms can be obtained from cell lysates of CHO produced cells, or from prokaryotic expression of a DNA encoding the pro form, in for example, E.coli. The pro form, which has an apparent molecular weight of about 50 kDa in mammalian cells, can then be isolated by HPLC and/or by gel electrophoresis, as described above. In order to detect and/or quantitate the amount of morphogenic protein present in a solution, an immunoassay may be performed to detect the morphogen using a polyclonal or monoclonal antibody specific for that protein. Here, soluble and mature forms of the morphogen also may be distinguished by using antibodies that discriminate between the two forms of the proteins as described above. Currently preferred assays include ELISAS and radioimmunassays, including standard competitor assays useful for quantitating the morphogen in a sample, where an unknown amount of sample morphogen is allowed to react with anti-morphogen antibody and this interaction is competed with a known amount of labeled antigen. The level of bound or free labeled antigen at equilibrium then is measured to quantitate the amount of unlabeled antigen in solution, the amount of sample antigen being proportional to the amount of free labeled antigen. Exemplary protocols for these assays are provided below. However, as will be appreciated by those skilled in the art, variations of these protocols, as well as other immunoassays, are well known in the literature and within the skill of the art. For example, in the ELISA protocol provided below, soluble OP-1 is identified in a sample using biotinylated anti-pro antiserum. Biotinylated antibodies can be visualized in a colormetric assay or in a che iluminescent assay, as described below. Alternatively, the antibody can be radio-labeled with a suitable molecule, such as 125 I. Still another protocol that may be used is a solid phase immunoassay, preferably using an affinity column with anti-morphogen antibody complexed to the matrix surface and over which a serum sample may be passed. A detailed description of useful immunoassays, including protocols and general considerations is provided in, for example. Molecular Cloning: A Laboratory Manual, Sambrook et al., eds. Cold Spring Harbor Press, New York, 1989, particularly Section 18. For serum assays, the serum preferably first is partially purified to remove some of the excess, contaminating serum proteins, such as serum albumin. Preferably the serum is extracted by precipitation in ammonium sulfate (e.g., 45%) such that the complex is precipitated. Further purification can be achieved using purification strategies that take advantage of the differential solubility of soluble morphogen complex or mature morphogens relative to that of the other proteins present in serum. Further purification also can be achieved by chromatographic techniques well known in the art. Soluble OP-1 may be detected using a polyclonal antibody specific for the OP-1 pro domain in an ELISA, as follows. 1 μg/100 μl of affinity-purified polyclonal rabbit IgG specific for OP-l-pro is added to each well of a 96-well plate and incubated at 37°C for an hour. The wells are washed four times with 0.167M sodium borate buffer with 0.15 M NaCl (BSB), pH 8.2, containing 0.1% Tween 20. To minimize non-specific binding, the wells are blocked by filling completely with 1% bovine serum albumin (BSA) in BSB and incubating for 1 hour at 37°C. The wells are then washed four times with BSB containing 0.1% Tween 20. A 100 μl aliquot of an appropriate dilution of each of the test samples of cell culture supernatant or serum sample is added to each well in triplicate and incubated at 37°C for 30 min. After incubation, 100 μl biotinylated rabbit anti-pro serum (stock solution is about 1 mg/ml and diluted 1:400 in BSB containing 1% BSA before use) is added to each well and incubated at 37°C for 30 min. The wells are then washed four times with BSB containing 0.1% Tween 20. 100 μl strepavidin-alkaline (Southern Biotechnology Associates, Inc. Birmingham, Alabama, diluted 1:2000 in BSB containing 0.1% Tween 20 before use) is added to each well and incubated at 37°C for 30 min. The plates are washed four times with 0.5M Tris buffered Saline (TBS), pH 7.2. 50μl substrate (ELISA Amplification System Kit, Life Technologies, Inc., Bethesda, MD) is added to each well incubated at room temperature for 15 min. Then, 50 μl amplifier (from the same amplification system kit) is added and incubated for another 15 min at room temperature. The reaction is stopped by the addition of 50 μl 0.3 M sulphuric acid. The OD at 490 nm of the solution in each well is recorded. To quantitate the level of soluble OP-1 in the sample, a standard curve is performed in parallel with the test samples. In the standard curve, known increasing amounts of purified OP-l-pro is added. Alternatively, using, for example, Lumi-phos 530 (Analytical Luminescence Laboratories) as the substrate and detection at 300-650 nm in a standard luminometer, complexes can be detected by chemiluminescence, which typically provides a more sensitive assay than detection by means of a visible color change. Morphogen (soluble or mature form) may be detected in a standard plated-based radioimmunoassay as follows. Empirically determined limiting levels of anti-morphogen antibody (e.g., anti-OP-1, typically 50-80 ng/well) are bound to wells of a PVC plate e.g., in 50 μl PBS phosphate buffered saline. After sufficient incubation to allow binding at room temperature, typically one hour, the plate is washed in a PBS/Tween 20 solution, ("washing buffer"), and 200 μl of block (3% BSA, O.lμ lysine in lxBSB) is added to each well and allowed to incubate for 1 hour, after which the wells are washed again in washing buffer. 40 μl of a sample composed of serially diluted plasma (preferably partially purified as described above) or morphogen standard (e.g., OP-1) is added to wells in triplicate. Samples preferably are diluted in PTTH (15 mM KH 2 P0 4 , 8 mM Na 2 P0 4 , 27 mM KC1, 137 mM NaCl, 0.05% Tween 20, 1 mg/ml HSA, 0.05% NaN 3 , pH 7.2). 10 μl of labelled competitor antigen, preferably 100,000-500,000 cpm/sample is added (e.g., 125 I OP-l, radiolabelled using standard procedures), and plates are incubated overnight at 4°C. Plates then are washed in washing buffer, and allowed to dry. Wells are cut apart and bound labelled OP-l counted in a standard gamma counter. The quantities of bound labelled antigen (e.g., 1 5 ι OP-l) measured in the presence and absence of sample then are compared, the difference being proportional to the amount of sample antigen (morphogen) present in the sample fluid. As a corollary assay method, immunoassays may be developed to detect endogenous anti-morphogen antibodies, and to distinguish between such antibodies to soluble or mature forms. Endogenous anti-morphogen antibodies have been detected in serum, and their level is known to increase, for example, upon implanting of an osteogenic device in a mammal. Without being limited to a particular theory, these antibodies may play a role in modulating morphogen activity by modulating the level of available protein in serum. Assays that monitor the level of endogenous antibodies in blood or their body fluids thus can be used in diagnostic assays to evaluate the status of a tissue, as well as to provide a means for monitoring the efficacy of a therapy for tissue regeneration. The currently preferred means for detecting endogenous anti-morphogen antibodies is by means of a standard Western blot. See, for example. Molecular Cloning: A Laboratory Manual Sambrook et al., eds., Cold Spring Harbor Press, New York, 1989, particularly pages 18.60-18.75, incorporated herein by reference, for a detailed description of these assays. Purified mature or soluble morphogen is electrophoresed on an SDS polyacrylamide gel under oxidized or reduced conditions designed to separate the proteins in solution, and the proteins then transferred to a polyvinylidene difluoride microporus membrane (0.45 μm pore sizes) using standard buffers and procedures. The filter then is incubated with the serum being tested (at various dilutions) . Antibodies bound to either the pro domain or the mature morphogen domain are detected by means of an anti-human antibody protein, e.g., goat anti-human Ig. Titers of the antimorphogen antibodies can be determined by further dilution of the serum until no signal is detected. X. Formulations and Methods for Administering Soluble Morphogens as Therapeutic Agents The soluble morphogens of this invention are particularly useful as therapeutic agents to regenerate diseased or damaged tissue in a mammal, particularly a human. The soluble morphogen complexes may be used to particular advantage in regeneration of damaged or diseased lung, heart, liver, kidney, nerve or pancreas tissue, as well as in the transplantation and/or grafting of these tissues and bone marrow, skin, gastrointestinal mucosa, and other living tissues. The soluble morphogen complexes described herein may be provided to an individual by any suitable means, preferably directly or systemically, e.g., parenterally or orally. Where the morphogen is to be provided directly (e.g., locally, as by injection, to a desired tissue site), or parenterally, such as by intravenous, subcutaneous, intramuscular, intraorbital, ophthalmic, intraventricular, intracranial, intracapsular. intraspinal, intracisternal, intraperitoneal, buccal, rectal, vaginal, intranasal or by aerosol administration, the soluble morphogen complex preferably comprises part of an aqueous solution. The solution is physiologically acceptable so that in addition to delivery of the desired morphogen to the patient, the solution does not otherwise adversely affect the patient's electrolyte and volume balance. The aqueous medium for the soluble morphogen thus may comprise normal physiologic saline (0.9% NaCl, 0.15M), pH 7-7.4. Soluble morphogens of this invention are readily purified from cultured cell media into a physiological buffer, as described above. In addition, and as described above, if desired, the soluble complexes may be formulated with one or more additional additives, including basic amino acids (e.g., L-arginine, lysine, betaine); non-ionic detergents (e.g. Tween-80 or NonIdet-120) and carrier proteins (e.g., serum albumin and casein) . Useful solutions for oral or parenteral administration may be prepared by any of the methods well known in the pharmaceutical art, described, for example, in Remington's Pharmaceutical Sciences, (Gennaro, A., ed. ) , Mack Pub., 1990. Formulations may include, for example, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like. Formulations for direct administration, in particular, may include glycerol and other compositions of high viscosity. Biocompatible, preferably bioresorbable polymers, including, for example, hyaluronic acid, collagen, tricalcium phosphate, polybutyrate, polylactide, polyglycolide and lactide/glycolide copolymers, may be useful excipients to control the release of the soluble morphogen in vivo. Other potentially useful parenteral delivery systems for these morphogens include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration may contain as excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. The soluble morphogens described herein also may be administered orally. Oral administration of proteins as therapeutics generally is not practiced as most proteins readily are degraded by digestive enzymes and acids in the mammalian digestive system before they can be absorbed into the bloodstream. However, the mature domains of the morphogens described herein typically are acid-stable and protease-resistant (see, for example, U.S. Pat. No. 4,968,590.) In addition, at least one morphogen, OP-l, has been identified, in mammary gland extract, colostrum and milk, as well as saliva. Moreover, the OP-l purified from mammary gland extract is morphogenically active. For example, this protein induces endochondral bone formation in mammals when implanted subcutaneously in association with a suitable matrix material, using a standard ij vivo bone assay, such as is disclosed in U.S. Pat. No. 4,968,590. In addition, endogenous morphogen also is detected in human serum (see above). Finally, comparative experiments with soluble and mature morphogens in a number of experiments defining morphogenic activity indicate that the non-covalent association of the pro domain with the dimeric species does not interfere with morphogenic activity. These findings indicate that oral and parenteral administration are viable means for administering morphogens to an individual, and that soluble morphogens have utility in systemic administration protocols. The soluble complexes provided herein also may be associated with molecules capable of targeting the morphogen to a desired tissue. For example, tetracycline and diphosphonates (bisphosphonates) are known to bind to bone mineral, particularly at zones of bone remodeling, when they are provided systemically in a mammal. Accordingly, these molecules may be included as useful agents for targeting soluble morphogens to bone tissue. Alternatively, an antibody or other binding protein that interacts specifically with a surface molecule on the desired target tissue cells also may be used. Such targeting molecules further may be covalently associated to the morphogen complex, e.g., by chemical crosslinking, or by using standard genetic engineering means to create, for example, an acid labile bond such as an Asp-Pro linkage. Useful targeting molecules may be designed, for example, using the single chain binding site technology disclosed, for example, in U.S. Pat. No. 5,091,513. Finally, the soluble morphogen complexes provided herein may be administered alone or in combination with other molecules known to have a beneficial effect on tissue morphogenesis, including molecules capable of tissue repair and regeneration and/or inhibiting inflammation. Examples of useful co actors for stimulating bone tissue growth in osteoporotic individuals, for example, include but are not limited to, vitamin D 3 , calcitonin, prostaglandins, parathyroid hormone, dexamethasone, estrogen and IGF-I or IGF-II. Useful cofactors for nerve tissue repair and regeneration may include nerve growth factors. Other useful cofactors include symptom-alleviating cofactors, including antiseptics, antibiotics, antiviral and antifungal agents and analgesics and anesthetics. The compounds provided herein can be formulated into pharmaceutical compositions by admixture with pharmaceutically acceptable nontoxic excipients and carriers. As noted above, such compositions may be prepared for parenteral administration, particularly in the form of liquid solutions or suspensions; for oral administration, particularly in the form of tablets or capsules; or intranasally, particularly in the form of powders, nasal drops or aerosols. Where adhesion to a tissue surface is desired the composition may include the morphogen dispersed in a fibrinogen-thrombin composition or other bioadhesive such as is disclosed, for example in PCT US91/09275, the disclosure of which is incorporated herein by reference. The composition then may be painted, sprayed or otherwise applied to the desired tissue surface. The compositions can be formulated for parenteral or oral administration to humans or other mammals in therapeutically effective amounts, e.g., amounts which provide appropriate concentrations of the morphogen to target tissue for a time sufficient to induce morphogenesis, including particular steps thereof, as described above. Where the soluble morphogen complex is to be used as part of a transplant procedure, the morphogen may be provided to the living tissue or organ to be transplanted prior to removal of the tissue or organ from the donor. The morphogen may be provided to the donor host directly, as by injection of a formulation comprising the soluble complex into the tissue, or indirectly, e.g., by oral or parenteral administration, using any of the means described above. Alternatively or, in addition, once removed from the donor, the organ or living tissue may be placed in a preservation solution containing the morphogen. In addition, the recipient also preferably is provided with the morphogen just prior to, or concommitant with, transplantation. In all cases, the soluble complex may be administered directly to the tissue at risk, as by injection to the tissue, or it may be provided systemically, either by oral or parenteral administration, using any of the methods and formulations described herein and/or known in the art. Where the morphogen comprises part of a tissue or organ preservation solution, any commercially available preservation solution may be used to advantage. A useful preservation solution is described in in PCT/US92/07358 (WO93/04692) , incorporated herein by reference. As will be appreciated by those skilled in the art, the concentration of the compounds described in a therapeutic composition will vary depending upon a number of factors, including the dosage of the drug to be administered, the chemical characteristics (e.g., hydrophobicity) of the compounds employed, and the route of administration. The preferred dosage of drug to be administered also is likely to depend on such variables as the type and extent of tissue loss or defect, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the compound, the presence and types of excipients in the formulation, and the route of administration. In general terms, the compounds of this invention may be provided in an aqueous physiological buffer solution containing about 0.001 to 10% w/v compound for parenteral administration. Typical dose ranges are from about 10 ng/kg to about 1 g/kg of body weight per day; a preferred dose range is from about 0.1 μg/kg to 100 mg/kg of body weight. No obvious morphogen-induced pathological lesions are induced when mature morphogen (e.g., OP-l, 20 μg) is administered daily to normal growing rats for 21 consecutive days. Moreover, 10 μg systemic injections of morphogen (e.g., OP-l) injected daily for 10 days into normal newborn mice does not produce any gross abnormalities. Where morphogens are administered systemically, in the methods of the present invention, preferably a large volume loading dose is used at the start of the treatment. The treatment then is continued with a maintenance dose. Further administration then can be determined by monitoring at intervals the levels of the morphogen in the blood. Other Embodiments The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: CREATIVE BIOMOLECULES, INC. (B) STREET: 35 SOUTH STREET (C) CITY: HOPKINTON (D) STATE: MA (E) COUNTRY: USA (F) POSTAL CODE (ZIP): 01748 (G) TELEPHONE: 1-508-435-9001 (H) TELEFAX: 1-508-435-0454 (I) TELEX: (ii) TITLE OF INVENTION: NOVEL MORPHOGENIC PROTEIN COMPOSITIONS OF MATTER (iii) NUMBER OF SEQUENCES: 23 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: PATENT ADMINISTRATOR/CREATIVE BIOMOLECULES, INC. (B) STREET: 35 SOUTH STREET (C) CITY: HOPKINTON (D) STATE: MA (E) COUNTRY: USA (F) ZIP: 01748 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 ( i) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: ( ii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: KELLEY, ROBIN, D. (B) REGISTRATION NUMBER: 34,637 (C) REFERENCE/DOCKET NUMBER: CRP-081CP (2) INFORMATION FOR SEQ ID N0:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1822 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: HOMO SAPIENS (F) TISSUE TYPE: HIPPOCAMPUS (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 49..1341 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN" /product= "OP1" /evidence= EXPERIMENTAL /standard name= "OP1" (xi) SEQUENCE DESCRIPTION: SEQ ID N0:1: GGTGCGGGCC CGGAGCCCGG AGCCCGGGTA GCGCGTAGAG CCGGCGCG ATG CAC GTG 57 Met His Val 1 CGC TCA CTG CGA GCT GCG GCG CCG CAC AGC TTC GTG GCG CTC TGG GCA 105 Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala 5 10 15 CCC CTG TTC CTG CTG CGC TCC GCC CTG GCC GAC TTC AGC CTG GAC AAC 153 Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn 20 25 30 35 GAG GTG CAC TCG AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG 201 Glu Val His Ser Ser Phe He His Arg Arg Leu Arg Ser Gin Glu Arg 40 45 50 CGG GAG ATG CAG CGC GAG ATC CTC TCC ATT TTG GGC TTG CCC CAC CGC 249 Arg Glu Met Gin Arg Glu He Leu Ser He Leu Gly Leu Pro His Arg 55 60 65 CCG CGC CCG CAC CTC CAG GGC AAG CAC AAC TCG GCA CCC ATG TTC ATG 297 Pro Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro Met Phe Met 70 75 80 CTG GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG GGC GGC GGG CCC GGC 345 Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly Gly Pro Gly 85 90 95 GGC CAG GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC 393 Gly Gin Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gin Gly 100 105 110 115 CCC CCT CTG GCC AGC CTG CAA GAT AGC CAT TTC CTC ACC GAC GCC GAC 441 Pro Pro Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr Asp Ala Asp 120 125 130 ATG GTC ATG AGC TTC GTC AAC CTC GTG GAA CAT GAC AAG GAA TTC TTC 489 Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe 135 140 145 CAC CCA CGC TAC CAC CAT CGA GAG TTC CGG TTT GAT CTT TCC AAG ATC 537 His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys He 150 155 160 CCA GAA GGG GAA GCT GTC ACG GCA GCC GAA TTC CGG ATC TAC AAG GAC 585 Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg He Tyr Lys Asp 165 170 175 TAC ATC CGG GAA CGC TTC GAC AAT GAG ACG TTC CGG ATC AGC GTT TAT 633 Tyr He Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg He Ser Val Tyr 180 185 190 195 CAG GTG CTC CAG GAG CAC TTG GGC AGG GAA TCG GAT CTC TTC CTG CTC 681 Gin Val Leu Gin Glu His Leu Gly Arg Glu Ser Asp Leu Phe Leu Leu 200 205 210 GAC AGC CGT ACC CTC TGG GCC TCG GAG GAG GGC TGG CTG GTG TTT GAC 729 Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp 215 220 225 ATC ACA GCC ACC AGC AAC CAC TGG GTG GTC AAT CCG CGG CAC AAC CTG 777 He Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu 230 235 240 GGC CTG CAG CTC TCG GTG GAG ACG CTG GAT GGG CAG AGC ATC AAC CCC 825 Gly Leu Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser He Asn Pro 245 250 255 AAG TTG GCG GGC CTG ATT GGG CGG CAC GGG CCC CAG AAC AAG CAG CCC 873 Lys Leu Ala Gly Leu He Gly Arg His Gly Pro Gin Asn Lys Gin Pro 260 265 270 275 TTC ATG GTG GCT TTC TTC AAG GCC ACG GAG GTC CAC TTC CGC AGC ATC 921 Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe Arg Ser He 280 285 290 CGG TCC ACG GGG AGC AAA CAG CGC AGC CAG AAC CGC TCC AAG ACG CCC 969 Arg Ser Thr Gly Ser Lys Gin Arg Ser Gin Asn Arg Ser Lys Thr Pro 295 300 305 AAG AAC CAG GAA GCC CTG CGG ATG GCC AAC GTG GCA GAG AAC AGC AGC 1017 Lys Asn Gin Glu Ala Leu Arg Met Ala Asn Val Ala Glu Asn Ser Ser 310 315 320 AGC GAC CAG AGG CAG GCC TGT AAG AAG CAC GAG CTG TAT GTC AGC TTC 1065 Ser Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe 325 330 335 CGA GAC CTG GGC TGG CAG GAC TGG ATC ATC GCG CCT GAA GGC TAC GCC 1113 Arg Asp Leu Gly Trp Gin Asp Trp He He Ala Pro Glu Gly Tyr Ala 340 345 350 355 GCC TAC TAC TGT GAG GGG GAG TGT GCC TTC CCT CTG AAC TCC TAC ATG 1161 Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met 360 365 370 AAC GCC ACC AAC CAC GCC ATC GTG CAG ACG CTG GTC CAC TTC ATC AAC 1209 Asn Ala Thr Asn His Ala He Val Gin Thr Leu Val His Phe He Asn 375 380 385 CCG GAA ACG GTG CCC AAG CCC TGC TGT GCG CCC ACG CAG CTC AAT GCC 1257 Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin Leu Asn Ala 390 395 400 ATC TCC GTC CTC TAC TTC GAT GAC AGC TCC AAC GTC ATC CTG AAG AAA 1305 He Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val He Leu Lys Lys 405 410 415 TAC AGA AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCCTCC 1351 Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His 420 425 430 GAGAATTCAG ACCCTTTGGG GCCAAGTTTT TCTGGATCCT CCATTGCTCG CCTTGGCCAG 1411 GAACCAGCAG ACCAACTGCC TTTTGTGAGA CCTTCCCCTC CCTATCCCCA ACTTTAAAGG 1471 TGTGAGAGTA TTAGGAAACA TGAGCAGCAT ATGGCTTTTG ATCAGTTTTT CAGTGGCAGC 1531 ATCCAATGAA CAAGATCCTA CAAGCTGTGC AGGCAAAACC TAGCAGGAAA AAAAAACAAC 1591 GCATAAAGAA AAATGGCCGG GCCAGGTCAT TGGCTGGGAA GTCTCAGCCA TGCACGGACT 1651 CGTTTCCAGA GGTAATTATG AGCGCCTACC AGCCAGGCCA CCCAGCCGTG GGAGGAAGGG 1711 GGCGTGGCAA GGGGTGGGCA CATTGGTGTC TGTGCGAAAG GAAAATTGAC CCGGAAGTTC 1771 CTGTAATAAA TGTCACAATA AAACGAATGA ATGAAAAAAA AAAAAAAAAA A 1822 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 431 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala 1 5 10 15 Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser 20 25 30 Leu Asp Asn Glu Val His Ser Ser Phe He His Arg Arg Leu Arg Ser 35 40 45 Gin Glu Arg Arg Glu Met Gin Arg Glu He Leu Ser He Leu Gly Leu 50 55 60 Pro His Arg Pro Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro 65 70 75 80 Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly 85 90 95 Gly Pro Gly Gly Gin Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser 100 105 110 Thr Gin Gly Pro Pro Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr 115 120 125 Asp Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys 130 135 140 Glu Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu 145 150 155 160 Ser Lys He Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg He 165 170 175 Tyr Lys Asp Tyr He Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg He 180 185 190 Ser Val Tyr Gin Val Leu Gin Glu His Leu Gly Arg Glu Ser Asp Leu 195 200 205 Phe Leu Leu Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu 210 215 220 Val Phe Asp He Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg 225 230 235 240 His Asn Leu Gly Leu Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser 245 250 255 He Asn Pro Lys Leu Ala Gly Leu He Gly Arg His Gly Pro Gin Asn 260 265 270 Lys Gin Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe 275 280 285 Arg Ser He Arg Ser Thr Gly Ser Lys Gin Arg Ser Gin Asn Arg Ser 290 295 300 Lys Thr Pro Lys Asn Gin Glu Ala Leu Arg Met Ala Asn Val Ala Glu 305 310 315 320 Asn Ser Ser Ser Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr 325 330 335 Val Ser Phe Arg Asp Leu Gly Trp Gin Asp Trp He He Ala Pro Glu 340 345 350 Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn 355 360 365 Ser Tyr Met Asn Ala Thr Asn His Ala He Val Gin Thr Leu Val His 370 375 380 Phe He Asn Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin 385 390 395 400 Leu Asn Ala He Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val He 405 410 415 Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His 420 425 430 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1873 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 104..1393 (D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN" /product= "MOPl" /note= "MOPl CDNA" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: CTGCAGCAAG TGACCTCGGG TCGTGGACCG CTGCCCTGCC CCCTCCGCTG CCACCTGGGG 60 CGGCGCGGGC CCGGTGCCCC GGATCGCGCG TAGAGCCGGC GCG ATG CAC GTG CGC 115 Met His Val Arg 1 TCG CTG CGC GCT GCG GCG CCA CAC AGC TTC GTG GCG CTC TGG GCG CCT 163 Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala Pro 5 10 15 20 CTG TTC TTG CTG CGC TCC GCC CTG GCC GAT TTC AGC CTG GAC AAC GAG 211 Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn Glu 25 30 35 GTG CAC TCC AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG CGG 259 Val His Ser Ser Phe He His Arg Arg Leu Arg Ser Gin Glu Arg Arg 40 45 50 GAG ATG CAG CGG GAG ATC CTG TCC ATC TTA GGG TTG CCC CAT CGC CCG 307 Glu Met Gin Arg Glu He Leu Ser He Leu Gly Leu Pro His Arg Pro 55 60 65 CGC CCG CAC CTC CAG GGA AAG CAT AAT TCG GCG CCC ATG TTC ATG TTG 355 Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro Met Phe Met Leu 70 75 80 GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG AGC GGG CCG GAC GGA CAG 403 Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly Pro Asp Gly Gin 85 90 95 100 GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC CCC CCT 451 Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gin Gly Pro Pro 105 110 115 TTA GCC AGC CTG CAG GAC AGC CAT TTC CTC ACT GAC GCC GAC ATG GTC 499 Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr Asp Ala Asp Met Val 120 125 130 ATG AGC TTC GTC AAC CTA GTG GAA CAT GAC AAA GAA TTC TTC CAC CCT 547 Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe His Pro 135 140 145 CGA TAC CAC CAT CGG GAG TTC CGG TTT GAT CTT TCC AAG ATC CCC GAG 595 Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys He Pro Glu 150 155 160 GGC GAA CGG GTG ACC GCA GCC GAA TTC AGG ATC TAT AAG GAC TAC ATC 643 Gly Glu Arg Val Thr Ala Ala Glu Phe Arg He Tyr Lys Asp Tyr He 165 170 175 180 CGG GAG CGA TTT GAC AAC GAG ACC TTC CAG ATC ACA GTC TAT CAG GTG 691 Arg Glu Arg Phe Asp Asn Glu Thr Phe Gin He Thr Val Tyr Gin Val 185 190 195 CTC CAG GAG CAC TCA GGC AGG GAG TCG GAC CTC TTC TTG CTG GAC AGC 739 Leu Gin Glu His Ser Gly Arg Glu Ser Asp Leu Phe Leu Leu Asp Ser 200 205 210 CGC ACC ATC TGG GCT TCT GAG GAG GGC TGG TTG GTG TTT GAT ATC ACA 787 Arg Thr He Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp He Thr 215 220 225 GCC ACC AGC AAC CAC TGG GTG GTC AAC CCT CGG CAC AAC CTG GGC TTA 835 Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu Gly Leu 230 235 240 CAG CTC TCT GTG GAG ACC CTG GAT GGG CAG AGC ATC AAC CCC AAG TTG 883 Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser He Asn Pro Lys Leu 245 250 255 260 GCA GGC CTG ATT GGA CGG CAT GGA CCC CAG AAC AAG CAA CCC TTC ATG 931 Ala Gly Leu He Gly Arg His Gly Pro Gin Asn Lys Gin Pro Phe Met 265 270 275 GTG GCC TTC TTC AAG GCC ACG GAA GTC CAT CTC CGT AGT ATC CGG TCC 979 Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg Ser He Arg Ser 280 285 290 ACG GGG GGC AAG CAG CGC AGC CAG AAT CGC TCC AAG ACG CCA AAG AAC 1027 Thr Gly Gly Lys Gin Arg Ser Gin Asn Arg Ser Lys Thr Pro Lys Asn 295 300 305 CAA GAG GCC CTG AGG ATG GCC AGT GTG GCA GAA AAC AGC AGC AGT GAC 1075 Gin Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn Ser Ser Ser Asp 310 315 320 CAG AGG CAG GCC TGC AAG AAA CAT GAG CTG TAC GTC AGC TTC CGA GAC 1123 Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp 325 330 335 340 CTT GGC TGG CAG GAC TGG ATC ATT GCA CCT GAA GGC TAT GCT GCC TAC 1171 Leu Gly Trp Gin Asp Trp He He Ala Pro Glu Gly Tyr Ala Ala Tyr 345 350 355 TAC TGT GAG GGA GAG TGC GCC TTC CCT CTG AAC TCC TAC ATG AAC GCC 1219 Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn Ala 360 365 370 ACC AAC CAC GCC ATC GTC CAG ACA CTG GTT CAC TTC ATC AAC CCA GAC 1267 Thr Asn His Ala He Val Gin Thr Leu Val His Phe He Asn Pro Asp 375 380 385 ACA GTA CCC AAG CCC TGC TGT GCG CCC ACC CAG CTC AAC GCC ATC TCT 1315 Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin Leu Asn Ala He Ser 390 395 400 GTC CTC TAC TTC GAC GAC AGC TCT AAT GTC ATC CTG AAG AAG TAC AGA 1363 Val Leu Tyr Phe Asp Asp Ser Ser Asn Val He Leu Lys Lys Tyr Arg 405 410 415 420 AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCTTCC TGAGACCCTG 1413 Asn Met Val Val Arg Ala Cys Gly Cys His 425 430 ACCTTTGCGG GGCCACACCT TTCCAAATCT TCGATGTCTC ACCATCTAAG TCTCTCACTG 1473 CCCACCTTGG CGAGGAGAAC AGACCAACCT CTCCTGAGCC TTCCCTCACC TCCCAACCGG 1533 AAGCATGTAA GGGTTCCAGA AACCTGAGCG TGCAGCAGCT GATGAGCGCC CTTTCCTTCT 1593 GGCACGTGAC GGACAAGATC CTACCAGCTA CCACAGCAAA CGCCTAAGAG CAGGAAAAAT 1653 GTCTGCCAGG AAAGTGTCCA GTGTCCACAT GGCCCCTGGC GCTCTGAGTC TTTGAGGAGT 1713 AATCGCAAGC CTCGTTCAGC TGCAGCAGAA GGAAGGGCTT AGCCAGGGTG GGCGCTGGCG 1773 TCTGTGTTGA AGGGAAACCA AGCAGAAGCC ACTGTAATGA TATGTCACAA TAAAACCCAT 1833 GAATGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAGAATTC 1873 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 430 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala 1 5 10 15 Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser 20 25 30 Leu Asp Asn Glu Val His Ser Ser Phe He His Arg Arg Leu Arg Ser 35 40 45 Gin Glu Arg Arg Glu Met Gin Arg Glu He Leu Ser He Leu Gly Leu 50 55 60 Pro His Arg Pro Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro 65 70 _ 75 80 Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly 85 90 95 Pro Asp Gly Gin Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr 100 105 110 Gin Gly Pro Pro Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr Asp 115 120 125 Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu 130 135 140 Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser 145 150 155 160 Lys He Pro Glu Gly Glu Arg Val Thr Ala Ala Glu Phe Arg He Tyr 165 170 175 Lys Asp Tyr He Arg Glu Arg Phe Asp Asn Glu Thr Phe Gin He Thr 180 185 190 Val Tyr Gin Val Leu Gin Glu His Ser Gly Arg Glu Ser Asp Leu Phe 195 200 205 Leu Leu Asp Ser Arg Thr He Trp Ala Ser Glu Glu Gly Trp Leu Val 210 215 220 Phe Asp He Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His 225 230 235 240 Asn Leu Gly Leu Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser He 245 250 255 Asn Pro Lys Leu Ala Gly Leu He Gly Arg His Gly Pro Gin Asn Lys 260 265 270 Gin Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg 275 280 285 Ser He Arg Ser Thr Gly Gly Lys Gin Arg Ser Gin Asn Arg Ser Lys 290 295 300 Thr Pro Lys Asn Gin Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn 305 310 315 320 Ser Ser Ser Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val 325 330 335 Ser Phe Arg Asp Leu Gly Trp Gin Asp Trp He He Ala Pro Glu Gly 340 345 350 Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser 355 360 365 Tyr Met Asn Ala Thr Asn His Ala He Val Gin Thr Leu Val His Phe 370 375 380 He Asn Pro Asp Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin Leu 385 390 395 400 Asn Ala He Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val He Leu 405 410 415 Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His 420 425 430 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1723 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (F) TISSUE TYPE: HIPPOCAMPUS (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 490..1696 (D) OTHER INFORMATION: /function-- "OSTEOGENIC PROTEIN" /product= "hOP2-PP" /note= "hOP2 (cDNA)" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: GGCGCCGGCA GAGCAGGAGT GGCTGGAGGA GCTGTGGTTG GAGCAGGAGG TGGCACGGCA 60 GGGCTGGAGG GCTCCCTATG AGTGGCGGAG ACGGCCCAGG AGGCGCTGGA GCAACAGCTC 120 CCACACCGCA CCAAGCGGTG GCTGCAGGAG CTCGCCCATC GCCCCTGCGC TGCTCGGACC 180 GCGGCCACAG CCGGACTGGC GGGTACGGCG GCGACAGAGG CATTGGCCGA GAGTCCCAGT 240 CCGCAGAGTA GCCCCGGCCT CGAGGCGGTG GCGTCCCGGT CCTCTCCGTC CAGGAGCCAG 300 GACAGGTGTC GCGCGGCGGG GCTCCAGGGA CCGCGCCTGA GGCCGGCTGC CCGCCCGTCC 360 CGCCCCGCCC CGCCGCCCGC CGCCCGCCGA GCCCAGCCTC CTTGCCGTCG GGGCGTCCCC 420 AGGCCCTGGG TCGGCCGCGG AGCCGATGCG CGCCCGCTGA GCGCCCCAGC TGAGCGCCCC 480 CGGCCTGCC ATG ACC GCG CTC CCC GGC CCG CTC TGG CTC CTG GGC CTG 528 Met Thr Ala Leu Pro Gly Pro Leu Trp Leu Leu Gly Leu 1 5 10 GCG CTA TGC GCG CTG GGC GGG GGC GGC CCC GGC CTG CGA CCC CCG CCC 576 Ala Leu Cys Ala Leu Gly Gly Gly Gly Pro Gly Leu Arg Pro Pro Pro 15 20 25 GGC TGT CCC CAG CGA CGT CTG GGC GCG CGC GAG CGC CGG GAC GTG CAG 624 Gly Cys Pro Gin Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Val Gin 30 35 40 45 CGC GAG ATC CTG GCG GTG CTC GGG CTG CCT GGG CGG CCC CGG CCC CGC 672 Arg Glu He Leu Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg 50 55 60 GCG CCA CCC GCC GCC TCC CGG CTG CCC GCG TCC GCG CCG CTC TTC ATG 720 Ala Pro Pro Ala Ala Ser Arg Leu Pro Ala Ser Ala Pro Leu Phe Met 65 70 75 CTG GAC CTG TAC CAC GCC ATG GCC GGC GAC GAC GAC GAG GAC GGC GCG 768 Leu Asp Leu Tyr His Ala Met Ala Gly Asp Asp Asp Glu Asp Gly Ala 80 85 90 CCC GCG GAG CGG CGC CTG GGC CGC GCC GAC CTG GTC ATG AGC TTC GTT 816 Pro Ala Glu Arg Arg Leu Gly Arg Ala Asp Leu Val Met Ser Phe Val 95 100 105 AAC ATG GTG GAG CGA GAC CGT GCC CTG GGC CAC CAG GAG CCC CAT TGG 864 Asn Met Val Glu Arg Asp Arg Ala Leu Gly His Gin Glu Pro His Trp 110 115 120 125 AAG GAG TTC CGC TTT GAC CTG ACC CAG ATC CCG GCT GGG GAG GCG GTC 912 Lys Glu Phe Arg Phe Asp Leu Thr Gin He Pro Ala Gly Glu Ala Val 130 135 140 ACA GCT GCG GAG TTC CGG ATT TAC AAG GTG CCC AGC ATC CAC CTG CTC 960 Thr Ala Ala Glu Phe Arg He Tyr Lys Val Pro Ser He His Leu Leu 145 150 155 AAC AGG ACC CTC CAC GTC AGC ATG TTC CAG GTG GTC CAG GAG CAG TCC 1008 Asn Arg Thr Leu His Val Ser Met Phe Gin Val Val Gin Glu Gin Ser 160 165 170 AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT CTT CAG ACG CTC CGA GCT 1056 Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp Leu Gin Thr Leu Arg Ala 175 180 185 GGA GAC GAG GGC TGG CTG GTG CTG GAT GTC ACA GCA GCC AGT GAC TGC 1104 Gly Asp Glu Gly Trp Leu Val Leu Asp Val Thr Ala Ala Ser Asp Cys 190 195 200 205 TGG TTG CTG AAG CGT CAC AAG GAC CTG GGA CTC CGC CTC TAT GTG GAG 1152 Trp Leu Leu Lys Arg His Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu 210 215 220 ACT GAG GAC GGG CAC AGC GTG GAT CCT GGC CTG GCC GGC CTG CTG GGT 1200 Thr Glu Asp Gly His Ser Val Asp Pro Gly Leu Ala Gly Leu Leu Gly 225 230 235 CAA CGG GCC CCA CGC TCC CAA CAG CCT TTC GTG GTC ACT TTC TTC AGG 1248 Gin Arg Ala Pro Arg Ser Gin Gin Pro Phe Val Val Thr Phe Phe Arg 240 245 250 GCC AGT CCG AGT CCC ATC CGC ACC CCT CGG GCA GTG AGG CCA CTG AGG 1296 Ala Ser Pro Ser Pro He Arg Thr Pro Arg Ala Val Arg Pro Leu Arg 255 260 265 AGG AGG CAG CCG AAG AAA AGC AAC GAG CTG CCG CAG GCC AAC CGA CTC 1344 Arg Arg Gin Pro Lys Lys Ser Asn Glu Leu Pro Gin Ala Asn Arg Leu 270 275 280 285 CCA GGG ATC TTT GAT GAC GTC CAC GGC TCC CAC GGC CGG CAG GTC TGC 1392 Pro Gly He Phe Asp Asp Val His Gly Ser His Gly Arg Gin Val Cys 290 295 300 CGT CGG CAC GAG CTC TAC GTC AGC TTC CAG GAC CTC GGC TGG CTG GAC 1440 Arg Arg His Glu Leu Tyr Val Ser Phe Gin Asp Leu Gly Trp Leu Asp 305 310 315 TGG GTC ATC GCT CCC CAA GGC TAC TCG GCC TAT TAC TGT GAG GGG GAG 1488 Trp Val He Ala Pro Gin Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu 320 325 330 TGC TCC TTC CCA CTG GAC TCC TGC ATG AAT GCC ACC AAC CAC GCC ATC 1536 Cys Ser Phe Pro Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala He 335 340 345 CTG CAG TCC CTG GTG CAC CTG ATG AAG CCA AAC GCA GTC CCC AAG GCG 1584 Leu Gin Ser Leu Val His Leu Met Lys Pro Asn Ala Val Pro Lys Ala 350 355 360 365 TGC TGT GCA CCC ACC AAG CTG AGC GCC ACC TCT GTG CTC TAC TAT GAC 1632 Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp 370 375 380 AGC AGC AAC AAC GTC ATC CTG CGC AAA GCC CGC AAC ATG GTG GTC AAG 1680 Ser Ser Asn Asn Val He Leu Arg Lys Ala Arg Asn Met Val Val Lys 385 390 395 GCC TGC GGC TGC CAC T GAGTCAGCCC GCCCAGCCCT ACTGCAG 1723 Ala Cys Gly Cys His 400 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Met Thr Ala Leu Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu Cys 1 5 10 15 Ala Leu Gly Gly Gly Gly Pro Gly Leu Arg Pro Pro Pro Gly Cys Pro 20 25 30 Gin Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Val Gin Arg Glu He 35 40 45 Leu Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg Ala Pro Pro 50 55 60 Ala Ala Ser Arg Leu Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu 65 70 75 80 Tyr His Ala Met Ala Gly Asp Asp Asp Glu Asp Gly Ala Pro Ala Glu 85 90 95 Arg Arg Leu Gly Arg Ala Asp Leu Val Met Ser Phe Val Asn Met Val 100 105 110 Glu Arg Asp Arg Ala Leu Gly His Gin Glu Pro His Trp Lys Glu Phe 115 120 125 Arg Phe Asp Leu Thr Gin He Pro Ala Gly_Glu Ala Val Thr Ala Ala 130 135 140 Glu Phe Arg He Tyr Lys Val Pro Ser He His Leu Leu Asn Arg Thr 145 150 155 160 Leu His Val Ser Met Phe Gin Val Val Gin Glu Gin Ser Asn Arg Glu 165 170 175 Ser Asp Leu Phe Phe Leu Asp Leu Gin Thr Leu Arg Ala Gly Asp Glu 180 185 190 Gly Trp Leu Val Leu Asp Val Thr Ala Ala Ser Asp Cys Trp Leu Leu 195 200 205 Lys Arg His Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu Thr Glu Asp 210 215 220 Gly His Ser Val Asp Pro Gly Leu Ala Gly Leu Leu Gly Gin Arg Ala 225 230 235 240 Pro Arg Ser Gin Gin Pro Phe Val Val Thr Phe Phe Arg Ala Ser Pro 245 250 255 Ser Pro He Arg Thr Pro Arg Ala Val Arg Pro Leu Arg Arg Arg Gin 260 265 270 Pro Lys Lys Ser Asn Glu Leu Pro Gin Ala Asn Arg Leu Pro Gly He 275 280 285 Phe Asp Asp Val His Gly Ser His Gly Arg Gin Val Cys Arg Arg His 290 295 300 Glu Leu Tyr Val Ser Phe Gin Asp Leu Gly Trp Leu Asp Trp Val He 305 310 315 320 Ala Pro Gin Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu Cys Ser Phe 325 330 335 Pro Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala He Leu Gin Ser 340 345 350 Leu Val His Leu Met Lys Pro Asn Ala Val Pro Lys Ala Cys Cys Ala 355 360 365 Pro Thr Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp Ser Ser Asn 370 375 380 Asn Val He Leu Arg Lys Ala Arg Asn Met Val Val Lys Ala Cys Gly 385 390 395 400 Cys His (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1926 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE: (A) ORGANISM: MURIDAE (F) TISSUE TYPE: EMBRYO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 93..1289 (D) OTHER INFORMATION: /function-- "OSTEOGENIC PROTEIN" /product= "mOP2-PP" /note= "mOP2 cDNA" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: GCCAGGCACA GGTGCGCCGT CTGGTCCTCC CCGTCTGGCG TCAGCCGAGC CCGACCAGCT 60 ACCAGTGGAT GCGCGCCGGC TGAAAGTCCG AG ATG GCT ATG CGT CCC GGG CCA 113 Met Ala Met Arg Pro Gly Pro 1 5 CTC TGG CTA TTG GGC CTT GCT CTG TGC GCG CTG GGA GGC GGC CAC GGT 161 Leu Trp Leu Leu Gly Leu Ala Leu Cys Ala Leu Gly Gly Gly His Gly 10 15 20 CCG CGT CCC CCG CAC ACC TGT CCC CAG CGT CGC CTG GGA GCG CGC GAG 209 Pro Arg Pro Pro His Thr Cys Pro Gin Arg Arg Leu Gly Ala Arg Glu 25 30 35 CGC CGC GAC ATG CAG CGT GAA ATC CTG GCG GTG CTC GGG CTA CCG GGA 257 Arg Arg Asp Met Gin Arg Glu He Leu Ala Val Leu Gly Leu Pro Gly 40 45 50 55 CGC CCC CGA CCC CGT GCA CAA CCC GCC GCT GCC CGG CAG CCA GCG TCC 305 Ark Pro Arg Pro Arg Ala Gin Pro Ala Ala Ala Arg Gin Pro Ala Ser 60 65 70 GCG CCC CTC TTC ATG TTG GAC CTA TAC CAC GCC ATG ACC GAT GAC GAC 353 Ala Pro Leu Phe Met Leu Asp Leu Tyr His Ala Met Thr Asp Asp Asp 75 80 85 GAC GGC GGG CCA CCA CAG GCT CAC TTA GGC CGT GCC GAC CTG GTC ATG 401 Asp Gly Gly Pro Pro Gin Ala His Leu Gly Arg Ala Asp Leu Val Met 90 95 100 AGC TTC GTC AAC ATG GTG GAA CGC GAC CGT ACC CTG GGC TAC CAG GAG 449 Ser Phe Val Asn Met Val Glu Arg Asp Arg Thr Leu Gly Tyr Gin Glu 105 110 115 CCA CAC TGG AAG GAA TTC CAC TTT GAC CTA ACC CAG ATC CCT GCT GGG 497 Pro His Trp Lys Glu Phe His Phe Asp Leu Thr Gin He Pro Ala Gly 120 125 130 135 GAG GCT GTC ACA GCT GCT GAG TTC CGG ATC TAC AAA GAA CCC AGC ACC 545 Glu Ala Val Thr Ala Ala Glu Phe Arg He Tyr Lys Glu Pro Ser Thr 140 145 150 CAC CCG CTC AAC ACA ACC CTC CAC ATC AGC ATG TTC GAA GTG GTC CAA 593 His Pro Leu Asn Thr Thr Leu His He Ser Met Phe Glu Val Val Gin 155 160 165 GAG CAC TCC AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT CTT CAG ACG 641 Glu His Ser Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp Leu Gin Thr 170 175 180 CTC CGA TCT GGG GAC GAG GGC TGG CTG GTG CTG GAC ATC ACA GCA GCC 689 Leu Arg Ser Gly Asp Glu Gly Trp Leu Val Leu Asp He Thr Ala Ala 185 190 195 AGT GAC CGA TGG CTG CTG AAC CAT CAC AAG GAC CTG GGA CTC CGC CTC 737 Ser Asp Arg Trp Leu Leu Asn His His Lys Asp Leu Gly Leu Arg Leu 200 205 210 215 TAT GTG GAA ACC GCG GAT GGG CAC AGC ATG GAT CCT GGC CTG GCT GGT 785 Tyr Val Glu Thr Ala Asp Gly His Ser Met Asp Pro Gly Leu Ala Gly 220 225 230 CTG CTT GGA CGA CAA GCA CCA CGC TCC AGA CAG CCT TTC ATG GTA ACC 833 Leu Leu Gly Arg Gin Ala Pro Arg Ser Arg Gin Pro Phe Met Val Thr 235 240 245 TTC TTC AGG GCC AGC CAG AGT CCT GTG CGG GCC CCT CGG GCA GCG AGA 881 Phe Phe Arg Ala Ser Gin Ser Pro Val Arg Ala Pro Arg Ala Ala Arg 250 255 260 CCA CTG AAG AGG AGG CAG CCA AAG AAA ACG AAC GAG CTT CCG CAC CCC 929 Pro Leu Lys Arg Arg Gin Pro Lys Lys Thr Asn Glu Leu Pro His Pro 265 270 275 AAC AAA CTC CCA GGG ATC TTT GAT GAT GGC CAC GGT TCC CGC GGC AGA 977 Asn Lys Leu Pro Gly He Phe Asp Asp Gly His Gly Ser Arg Gly Arg 280 285 290 295 GAG GTT TGC CGC AGG CAT GAG CTC TAC GTC AGC TTC CGT GAC CTT GGC 1025 Glu Val Cys Arg Arg His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly 300 305 310 TGG CTG GAC TGG GTC ATC GCC CCC CAG GGC TAC TCT GCC TAT TAC TGT 1073 Trp Leu Asp Trp Val He Ala Pro Gin Gly Tyr Ser Ala Tyr Tyr Cys 315 320 325 GAG GGG GAG TGT GCT TTC CCA CTG GAC TCC TGT ATG AAC GCC ACC AAC 1121 Glu Gly Glu Cys Ala Phe Pro Leu Asp Ser Cys Met Asn Ala Thr Asn 330 335 340 CAT GCC ATC TTG CAG TCT CTG GTG CAC CTG ATG AAG CCA GAT GTT GTC 1169 His Ala He Leu Gin Ser Leu Val His Leu Met Lys Pro Asp Val Val 345 350 355 CCC AAG GCA TGC TGT GCA CCC ACC AAA CTG AGT GCC ACC TCT GTG CTG 1217 Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr Ser Val Leu 360 365 370 375 TAC TAT GAC AGC AGC AAC AAT GTC ATC CTG CGT AAA CAC CGT AAC ATG 1265 Tyr Tyr Asp Ser Ser Asn Asn Val He Leu Arg Lys His Arg Asn Met 380 385 390 GTG GTC AAG GCC TGT GGC TGC CAC TGAGGCCCCG CCCAGCATCC TGCTTCTACT 1319 Val Val Lys Ala Cys Gly Cys His 395 ACCTTACCAT CTGGCCGGGC CCCTCTCCAG AGGCAGAAAC CCTTCTATGT TATCATAGCT 1379 CAGACAGGGG CAATGGGAGG CCCTTCACTT CCCCTGGCCA CTTCCTGCTA AAATTCTGGT 1439 CTTTCCCAGT TCCTCTGTCC TTCATGGGGT TTCGGGGCTA TCACCCCGCC CTCTCCATCC 1499 TCCTACCCCA AGCATAGACT GAATGCACAC AGCATCCCAG AGCTATGCTA ACTGAGAGGT 1559 CTGGGGTCAG CACTGAAGGC CCACATGAGG AAGACTGATC CTTGGCCATC CTCAGCCCAC 1619 AATGGCAAAT TCTGGATGGT CTAAGAAGGC CCTGGAATTC TAAACTAGAT GATCTGGGCT 1679 CTCTGCACCA TTCATTGTGG CAGTTGGGAC ATTTTTAGGT ATAACAGACA CATACACTTA 1739 GATCAATGCA TCGCTGTACT CCTTGAAATC AGAGCTAGCT TGTTAGAAAA AGAATCAGAG 1799 CCAGGTATAG CGGTGCATGT CATTAATCCC AGCGCTAAAG AGACAGAGAC AGGAGAATCT 1859 CTGTGAGTTC AAGGCCACAT AGAAAGAGCC TGTCTCGGGA GCAGGAAAAA AAAAAAAAAC 1919 GGAATTC 1926 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 399 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Met Ala Met Arg Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu Cys 1 5 10 15 Ala Leu Gly Gly Gly His Gly Pro Arg Pro Pro His Thr Cys Pro Gin 20 25 30 Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Met Gin Arg Glu He Leu 35 40 45 Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg Ala Gin Pro Ala 50 55 60 Ala Ala Arg Gin Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu Tyr 65 70 75 80 His Ala Met Thr Asp Asp Asp Asp Gly Gly Pro Pro Gin Ala His Leu 85 90 95 Gly Arg Ala Asp Leu Val Met Ser Phe Val Asn Met Val Glu Arg Asp 100 105 110 Arg Thr Leu Gly Tyr Gin Glu Pro His Trp Lys Glu Phe His Phe Asp 115 120 125 Leu Thr Gin He Pro Ala Gly Glu Ala Val Thr Ala Ala Glu Phe Arg 130 135 140 He Tyr Lys Glu Pro Ser Thr His Pro Leu Asn Thr Thr Leu His He 145 150 155 160 Ser Met Phe Glu Val Val Gin Glu His Ser Asn Arg Glu Ser Asp Leu 165 170 175 Phe Phe Leu Asp Leu Gin Thr Leu Arg Ser Gly Asp Glu Gly Trp Leu 180 185 190 Val Leu Asp He Thr Ala Ala Ser Asp Arg Trp Leu Leu Asn His His 195 200 205 Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu Thr Ala Asp Gly His Ser 210 215 220 Met Asp Pro Gly Leu Ala Gly Leu Leu Gly Arg Gin Ala Pro Arg Ser 225 230 235 240 Arg Gin Pro Phe Met Val Thr Phe Phe Arg Ala Ser Gin Ser Pro Val 245 250 255 Arg Ala Pro Arg Ala Ala Arg Pro Leu Lys Arg Arg Gin Pro Lys Lys 260 265 270 Thr Asn Glu Leu Pro His Pro Asn Lys Leu Pro Gly He Phe Asp Asp 275 280 285 Gly His Gly Ser Arg Gly Arg Glu Val Cys Arg Arg His Glu Leu Tyr 290 295 300 Val Ser Phe Arg Asp Leu Gly Trp Leu Asp Trp Val He Ala Pro Gin 305 310 315 320 Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asp 325 330 335 Ser Cys Met Asn Ala Thr Asn His Ala He Leu Gin Ser Leu Val His 340 345 350 Leu Met Lys Pro Asp Val Val Pro Lys Ala Cys Cys Ala Pro Thr Lys 355 360 365 Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp Ser Ser Asn Asn Val He 370 375 380 Leu Arg Lys His Arg Asn Met Val Val Lys Ala Cys Gly Cys His 385 390 395 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 399 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..399 (D) OTHER INFORMATION: /note= "PRE-PR0-0P3 (MOUSE)" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Met Ala Ala Arg Pro Gly Leu Leu Trp Leu Leu Gly Leu Ala Leu Cys 1 5 10 15 Val Leu Gly Gly Gly His Leu Ser His Pro Pro His Val Phe Pro Gin 20 25 30 Arg Arg Leu Gly Val Arg Glu Pro Arg Asp Met Gin Arg Glu He Arg 35 40 45 Glu Val Leu Gly Leu Ala Gly Arg Pro Arg Ser Arg Ala Pro Val Gly 50 55 60 Ala Ala Gin Gin Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu Tyr 65 70 75 80 Arg Ala Met Thr Asp Asp Ser Gly Gly Gly Thr Pro Gin Pro His Leu 85 90 95 Asp Arg Ala Asp Leu He Met Ser Phe Val Asn He Val Glu Arg Asp 100 105 110 Arg Thr Leu Gly Tyr Gin Glu Pro His Trp Lys Glu Phe-His Phe Asp 115 120 125 Leu Thr Gin He Pro Ala Gly Glu Ala Val Thr Ala Ala Glu Phe Arg 130 135 140 He Tyr Lys Glu Pro Ser Thr His Pro Leu Asn Thr Thr Leu His He 145 150 155 160 Ser Met Phe Glu Val Val Gin Glu His Ser Asn Arg Glu Ser Asp Leu 165 170 175 Phe Phe Leu Asp Leu Gin Thr Leu Arg Ser Gly Asp Glu Gly Trp Leu 180 185 190 Val Leu Asp He Thr Ala Ala Ser Asp Arg Trp Leu Leu Asn His His 195 200 205 Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu Thr Glu Asp Gly His Ser 210 215 220 He Asp Pro Gly Leu Ala Gly Leu Leu Gly Arg Gin Ala Pro Arg Ser 225 230 235 240 Arg Gin Pro Phe Met Val Gly Phe Phe Arg Ala Asn Gin Ser Pro Val 245 250 255 Arg Ala Pro Arg Thr Ala Arg Pro Leu Lys Lys Lys Gin Leu Asn Gin 260 265 270 He Asn Gin Leu Pro His Ser Asn Lys His Leu Gly He Leu Asp Asp 275 280 285 Gly His Gly Ser His Gly Arg Glu Val Cys Arg Arg His Glu Leu Tyr 290 295 300 Val Ser Phe Arg Asp Leu Gly Trp Leu Asp Ser Val He Ala Pro Gin 305 310 315 320 Gly Tyr Ser Ala Tyr Tyr Cys Ala Gly Glu Cys He Tyr Pro Leu Asn 325 330 335 Ser Cys Met Asn Ser Thr Asn His Ala Thr Met Gin Ala Leu Val His 340 345 350 Leu Met Lys Pro Asp He He Pro Lys Val Cys Cys Val Pro Thr Glu 355 360 365 Leu Ser Ala He Ser Leu Leu Tyr Tyr Asp Arg Asn Asn Asn Val He 370 375 380 Leu Arg Arg Glu Arg Asn Met Val Val Gin Ala Cys Gly Cys His 385 390 395 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 396 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..396 (D) OTHER INFORMATION: /note= "PRE-PRO-BMP2 (HUMAN)" (x) PUBLICATION INFORMATION: (A) AUTHORS: W0ZNEY, (C) JOURNAL: SCIENCE (D) VOLUME: 242 (F) PAGES: 1528-1534 (G) DATE: 1988 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Met Val Ala Gly Thr Arg Cys Leu Leu Ala Leu Leu Leu Pro Gin Val 1 5 10 15 Leu Leu Gly Gly Ala Ala Gly Leu Val Pro Glu Leu Gly Arg Arg Lys 20 25 30 Phe Ala Ala Ala Ser Ser Gly Arg Pro Ser Ser Gin Pro Ser Asp Glu 35 40 45 Val Leu Ser Glu Phe Glu Leu Arg Leu Leu Ser Met Phe Gly Leu Lys 50 55 60 Gin Arg Pro Thr Pro Ser Arg Asp Ala Val Val Pro Pro Tyr Met Leu 65 70 75 80 Asp Leu Tyr Arg Arg His Ser Gly Gin Pro Gly Ser Pro Ala Pro Asp 85 90 95 His Arg Leu Glu Arg Ala Ala Ser Arg Ala Asn Thr Val Arg Ser Phe 100 105 110 His His Glu Glu Ser Leu Glu Glu Leu Pro Glu Thr Ser Gly Lys Thr 115 120 125 Thr Arg Arg Phe Phe Phe Asn Leu Ser Ser He Pro Thr Glu Glu Phe 130 135 140 He Thr Ser Ala Glu Leu Gin Val Phe Arg Glu Gin Met Gin Asp Ala 145 150 155 160 Leu Gly Asn Asn Ser Ser Phe His His Arg He Asn He Tyr Glu He 165 170 175 He Lys Pro Ala Thr Ala Asn Ser Lys Phe Pro Val Thr Arg Leu Leu 180 185 190 Asp Thr Arg Leu Val Asn Gin Asn Ala Ser Arg Trp Glu Ser Phe Asp 195 200 205 Val Thr Pro Ala Val Met Arg Trp Thr Ala Gin Gly His Ala Asn His 210 215 220 Gly Phe Val Val Glu Val Ala His Leu Glu Glu Lys Gin Gly Val Ser Lys 225 230 235 240 Arg His Val Arg He Ser Arg Ser Leu His Gin Asp Glu His Ser Trp 245 250 255 Ser Gin He Arg Pro Leu Leu Val Thr Phe Gly His Asp Gly Lys Gly 260 265 270 His Pro Leu His Lys Arg Glu Lys Arg Gin Ala Lys His Lys Gin Arg 275 280 285 Lys Arg Leu Lys Ser Ser Cys Lys Arg His Pro Leu Tyr Val Asp Phe 290 295 300 305 Ser Asp Val Gly Trp Asn Asp Trp He Val Ala Pro Pro Gly Tyr His 310 315 320 Ala Phe Tyr Cys His Gly Glu Cys Pro Phe Pro Leu Ala Asp His Leu 325 330 335 Asn Ser Thr Asn His Ala He Val Gin Thr Leu Val Asn Ser Val Asn 340 345 350 Ser Lys He Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Ser Ala He 355 360 365 370 Ser Met Leu Tyr Leu Asp Glu Asn Glu Lys Val Val Leu Lys Asn Tyr 375 380 385 Gin Asp Met Val Val Glu Gly Cys Gly Cys Arg 390 395 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 408 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..408 (D) OTHER INFORMATION: /note= "PRE-PR0-BMP4 (HUMAN)" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Met He Pro Gly Asn Arg Met Leu Met Val Val Leu Leu Cys Gin Val 1 5 10 15 Leu Leu Gly Gly Ala Ser His Ala Ser Leu He Pro Glu Thr Gly Lys 20 25 30 Lys Lys Val Ala Glu He Gin Gly His Ala Gly Gly Arg Arg Ser Gly 35 40 45 Gin Ser His Glu Leu Leu Arg Asp Phe Glu Ala Thr Leu Leu Gin Met 50 55 60 Phe Gly Leu Arg Arg Arg Pro Gin Pro Ser Lys Ser Ala Val He Pro 65 70 75 80 Asp Tyr Met Arg Asp Leu Tyr Arg Leu Gin Ser Gly Glu Glu Glu Glu 85 90 95 Glu Gin He His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala Ser 100 105 110 Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu HisJLeu Glu Asn 115 120 125 He Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu 130 135 140 Ser Ser He Pro Glu Asn Glu Val He Ser Ser Ala Glu Leu Arg Leu 145 150 155 160 Phe Arg Glu Gin Val Asp Gin Gly Pro Asp Trp Glu Arg Gly Phe His 165 170 175 Arg He Asn He Tyr Glu Val Met Lys Pro Pro Ala Glu Val Val Pro 180 185 190 Gly His Leu He Thr Arg Leu Leu Asp Thr Arg Leu Val His His Asn 195 200 205 Val Thr-Arg Trp Glu Thr Phe Asp Val Ser Pro Ala Val Leu Arg Trp 210 215 220 Thr Arg Glu Lys Gin Pro Asn Tyr Gly Leu Ala He Glu Val Thr His 225 230 235 240 Leu His Gin Thr Arg Thr His Gin Gly Gin His Val Arg He Ser Arg 245 250 255 Ser Leu Pro Gin Gly Ser Gly Asn Trp Ala Gin Leu Arg Pro Leu Leu 260 265 270 Val Thr Phe Gly His Asp Gly Arg Gly His Ala Leu Thr Arg Arg Arg 275 280 285 Arg Ala Lys Arg Ser Pro Lys His His Ser Gin Arg Ala Arg Lys Lys 290 295 300 Asn Lys Asn Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Phe Asp 305 310 315 320 Val Gly Trp Asn Asp Trp He Val Ala Pro Pro Gly Tyr Gin Ala Phe 325 330 335 Tyr Cys His Gly Asp Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser 340 345 350 Thr Asn His Ala He Val Gin Thr Leu Val Asn Ser Val Asn Ser Ser 355 360 365 He Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Ser Ala He Ser Met 370 375 380 Leu Tyr Leu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gin Glu 385 390 395 Met Val Val Glu Gly Cys Gly Cys Arg 400 405 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 588 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D)-TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..588 (D) OTHER INFORMATION: /note= "PRE-PRO-DPP" (x) PUBLICATION INFORMATION: (A) AUTHORS: PADGETT, (C) JOURNAL: NATURE (D) VOLUME: 325 (F) PAGES: 81-84 (G) DATE: 1987 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Met Arg Ala Trp Leu Leu Leu Leu Ala Val Leu Ala Thr Phe Gin Thr 1 5 10 15 He Val Arg Val Ala Ser Thr Glu Asp He Ser Gin Arg Phe He Ala 20 25 30 Ala He Ala Pro Val Ala Ala His He Pro Leu Ala Ser Ala Ser Gly 35 40 45 Ser Gly Ser Gly Arg Ser Gly Ser Arg Ser Val Gly Ala Ser Thr Ser 50 55 60 Thr Ala Leu Ala Lys Ala Phe Asn Pro Phe Ser Glu Pro Ala Ser Phe 65 70 75 80 Ser Asp Ser Asp Lys Ser His Arg Ser Lys Thr Asn Lys Lys Pro Ser 85 90 95 Lys Ser Asp Ala Asn Arg Gin Phe Asn Glu Val His Lys Pro Arg Thr 100 105 110 Asp Gin Leu Glu Asn Ser Lys Asn Lys Ser Lys Gin Leu Val Asn Lys Pro 115 120 125 Asn His Asn Lys Met Ala Val Lys Glu Gin Arg Ser His His Lys Lys 130 135 140 145 Ser His His His Arg Ser His Gin Pro Lys Gin Ala Ser Ala Ser Thr 150 155 160 Glu Ser His Gin Ser Ser Ser He Glu Ser He Phe Val Glu Glu Pro 165 170 175 Thr Leu Val Leu Asp Arg Glu Val Ala Ser He Asn Val Pro Ala Ser 180 185 190 Ala Lys Ala He He Ala Glu Gin Gly Pro Ser Thr Tyr Ser Lys Glu 195 200 205 Ala Leu He Lys Asp Lys Leu Lys Pro Asp Pro Ser Thr Leu Val Glu 210 215 220 225 He Glu Lys Ser Leu Leu Ser Leu Phe Asn Met Lys Arg Pro Pro Lys 230 235 240 He Asp Arg Ser Lys He He He Pro Glu Pro Met Lys Lys Leu Tyr 245 250 255 Ala Glu He Met Gly His Glu Leu Asp Ser Val Asn He Pro Lys Pro 260 265 270 Gly Leu Leu Thr Lys Ser Ala Asn Thr Val Arg Ser Phe Thr His Lys 275 280 285 Asp Ser Lys He Asp Asp Arg Phe Pro His His His Arg Phe Arg Leu 290 295 300 305 His Phe Asp Val Lys Ser He Pro Ala Asp Glu Lys Leu Lys Ala Ala 310 315 320 Glu Leu Gin Leu Thr Arg Asp Ala Leu Ser Gin Gin Val Val Ala Ser 325 330 335 Arg Ser Ser Ala Asn Arg Thr Arg Tyr Gin Val Leu Val Tyr Asp He 340 345 350 Thr Arg Val Gly Val Arg Gly Gin Arg Glu Pro Ser Tyr Leu Leu Leu 355 360 365 Asp Thr Lys Thr Val Arg Leu Asn Ser Thr Asp Thr Val Ser Leu Asp 370 375 380 385 Val Gin Pro Ala Val Asp Arg Trp Leu Ala Ser Pro Gin Arg Asn Tyr 390 395 400 Gly Leu Leu Val Glu Val Arg Thr Val Arg Ser Leu Lys Pro Ala Pro 405 410 415 His His His Val Arg Leu Arg Arg Ser Ala Asp Glu Ala His Glu Arg 420 425 430 Trp Gin His Lys Gin Pro Leu Leu Phe Thr Tyr Thr Asp Asp Gly Arg 435 440 445 His Lys Ala Arg Ser He Arg Asp Val Ser Gly Gly Glu Gly Gly Gly 450 455 460 465 Lys Gly Gly Arg Asn Lys Arg His Ala Arg Arg Pro Thr Arg Arg Lys 470 475 480 Asn His Asp Asp Thr Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser 485 490 495 Asp Val Gly Trp Asp Asp Trp He Val Ala Pro Leu Gly Tyr Asp Ala 500 505 510 Tyr Tyr Cys His Gly Lys Cys Pro Phe Pro Leu Ala Asp His Phe Asn 515 520 525 Ser Thr Asn His Ala Val Val Gin Thr Leu Val Asn Asn Met Asn Pro 530 535 540 545 Gly Lys Val Pro Lys Ala Cys Cys Val Pro Thr Gin Leu Asp Ser Val 550 555 560 Ala Met Leu Tyr Leu Asn Asp Gin Ser Thr Val Val Leu Lys Asn Tyr 565 570 575 Gin Glu Met Thr Val Val Gly Cys Gly Cys Arg 580 585 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 359 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..359 (D) OTHER INFORMATION: /note= "PRE-PR0-VG1" (x) PUBLICATION INFORMATION: (A) AUTHORS: WEEKS, (C) JOURNAL: CELL (D) VOLUME: 51 (F) PAGES: 861-867 (G) DATE: 1987 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Met Val Trp Leu Arg Leu Trp Ala Phe Leu His He Leu Ala He Val 1 5 10 15 Thr Leu Asp Pro Glu Leu Lys Arg Arg Glu Glu Leu Phe Leu Arg Ser 20 25 30 Leu Gly Phe Ser Ser Lys Pro Asn Pro Val Ser Pro Pro Pro Val Pro 35 40 45 Ser He Leu Trp Arg He Phe Asn Gin Arg Met Gly Ser Ser He Gin 50 55 60 Lys Lys Lys Pro Asp Leu Cys Phe Val Glu Glu Phe Asn Val Pro Gly 65 70 75 80 Ser Val He Arg Val Phe Pro Asp Gin Gly Arg Phe He He Pro Tyr 85 90 95 Ser Asp Asp He His Pro Thr Gin Cys Leu Glu Lys Arg Leu Phe Phe 100 105 110 Asn He Ser Ala He Glu Lys Glu Glu Arg Val Thr Met Gly Ser Gly 115 120 125 He Glu Val Glu Pro Glu His Leu Leu Arg Lys Gly He Asp Leu Arg 130 135 140 Leu Tyr Arg Thr Leu Gin He Thr Leu Lys Gly Met 145 150 155 Gly Arg Ser Lys Thr Ser Arg Lys Leu Leu Val Ala Gin Thr Phe Arg 160 165 170 Leu Leu His Lys Ser Leu Phe Phe Asn Leu Thr Glu He Cys Gin Ser 180 185 190 Trp Gin Asp Pro Leu Lys Asn Leu Gly Leu Val Leu Glu He Phe Pro 195 200 205 Lys Lys Glu Ser Ser Trp Met Ser Thr Ala Asn Asp Glu Cys Lys Asp He 210 215 220 225 Gin Thr Phe Leu Tyr Thr Ser Leu Leu Thr Val Thr Leu Asn Pro Leu 230 235 240 Arg Cys Lys Arg Pro Arg Arg Lys Arg Ser Tyr Ser Lys Leu Pro Phe 245 250 255 Thr Ala Ser Asn He Cys Lys Lys Arg His Leu Tyr Val Glu Phe Lys 260 265 270 Asp Val Gly Trp Gin Asn Trp Val He Ala Pro Gin Gly Tyr Met Ala 275 280 285 290 Asn Tyr Cys Tyr Gly Glu Cys Pro Tyr Pro Leu Thr Glu He Leu Asn 295 300 305 Gly Ser Asn His Ala He Leu Gin Thr Leu Val His Ser He Glu Pro 310 315 320 Glu Asp He Pro Leu Pro Cys Cys Val Pro Thr Lys Met Ser Pro He 325 330 335 Ser Met Leu Phe Tyr Asp Asn Asn Asp Asn Val Val Leu Arg His Tyr 340 345 350 Glu Asn Met Ala Val Asp Glu Cys Gly Cys Arg 355 360 365 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 438 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..438 (D) OTHER INFORMATION: /note= "PRE-PRO-VGR1" (X) PUBLICATION INFORMATION: (A) AUTHORS: LYONS, (C) JOURNAL: Proc. Natl. Acad. Sci. U.S.A. (D) VOLUME: 86 (F) PAGES: 4554-4558 (G) DATE: 1989 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Met Arg Lys Met Gin Lys Glu He Leu Ser Val Leu Gly Pro Pro His 1 5 10 15 Arg Pro Arg Pro Leu His Gly Leu Gin Gin Pro Gin Pro Pro Val Leu 20 25 30 Pro Pro Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Thr Ala Asp Glu 35 40 45 Glu Pro Pro Pro Gly Arg Leu Lys Ser Ala Pro Leu Phe Met Leu Asp 50 55 60 Leu Ser Asn Asp Asp Glu Glu Asp Gly Ala Ser Glu 70 75 80 Glu Pro Gly Ser His Gly Gly Ala Ser Ser Ser Gin 85 90 95 Ser Pro Gly Ala Ala His Ser Leu Asn Arg Lys Ser 105 110 Gly Pro Gly Gly Gly Ala Ser Pro Leu Thr Ser Ala 120 125 Phe Leu Asn Asp Ala Asp Met Val Met Ser Phe Val 135 140 Tyr Asp Lys Glu Phe Ser Pro His Gin Arg His His 150 155 160 Lys Glu Phe Lys Phe Asn Leu Ser Gin He Pro Glu Gly Glu Ala Val 165 170 175 Thr Ala Ala Glu Phe Arg Val Tyr Lys Asp Cys Val Val Gly Ser Phe 180 185 190 Lys Asn Gin Thr Phe Leu He Ser He Tyr Gin Val Leu Gin Glu Ala 195 200 205 Gin His Arg Asp Ser Asp Leu Phe Leu Leu Asp Thr Arg Val Val Trp 210 215 220 Ala Ser Glu Glu Gly Trp Leu Glu Phe Asp He Thr Ala Thr Ser Asn 225 230 235 240 Leu Trp Val Val He Pro Gin His Asn Met Gly Leu Gin Leu Ser Val 245 250 255 Val Thr Arg Asp Gly Leu His Val Asn Pro Arg Ala Ala Gly Leu Val 260 265 270 Gly Arg Asp Gly Pro Tyr Asp Lys Gin Pro Phe Met Val Ala Phe Phe 275 280 285 Lys Val Ser Glu Val His Val Arg Thr Thr Arg Ser Ala Ser Ser Arg 290 295 300 Arg Arg Gin Gin Ser Arg Asn Arg Ser Thr Gin Ser Gin Asp Val Ser 305 310 315 320 Arg Gly Ser Gly Ser Ser Asp Tyr Asn Gly Ser Glu Leu Lys Thr Ala 325 330 335 Cys Lys Lys His Glu Leu Tyr Val Ser Phe Gin Asp Leu Gly Trp Gin 340 345 350 Asp Trp He He Ala Pro Lys Gly Tyr Ala Ala Asn Tyr Cys Asp Gly 355 360 365 Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala 370 375 380 He Val Gin Thr Leu Val His Leu Met Asn Pro Glu Thr Val Pro Lys 385 390 395 400 Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala He Ser Val Leu Tyr Phe 405 410 415 Asp Asp Asn Ser Asn Val He Leu Lys Lys Tyr Arg Asn Met Val Val 420 425 430 Arg Ala Cys Gly Cys His 435 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 372 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..372 (D) OTHER INFORMATION: /note= "PRE-PRO-GDF-1" (x) PUBLICATION INFORMATION: (A) AUTHORS: LEE, (B) TITLE: EXPRESSION OF GROWTH/DIFFERENTIATION FACTOR 1 (C) JOURNAL: Proc. Natl. Acad. Sci. U.S.A. (D) VOLUME: 88 (F) PAGES: 4250-4254 (G) DATE: MAY-1991 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15; Met Pro Pro Pro Gin Gin Gly Pro Cys Gly His His Leu Leu Leu Leu 1 5 10 15 Leu Ala Leu Leu Leu Pro Ser Leu Pro Leu Thr Arg Ala Pro Val Pro 20 25 30 Pro Gly Pro Ala Ala Ala Leu Leu Gin Ala Leu Gly Leu Arg Asp Glu 35 40 45 Pro Gin Gly Ala Pro Arg Leu Arg Pro Val Pro Pro Val Met Trp Arg 50 55 60 Leu Phe Arg Arg Arg Asp Pro Gin Glu Thr Arg Ser Gly Ser Arg Arg 65 70 75 80 Thr Ser Pro Gly Val Thr Leu Gin Pro Cys His Val Glu Glu Leu Gly 85 90 95 Val Ala Gly Asn He Val Arg His He Pro Asp Arg Gly Ala Pro Thr 100 105 110 Arg Ala Ser Glu Pro Val Ser Ala Ala Gly His Cys Pro Glu Trp Thr 115 120 125 Val Val Phe Asp Leu Ser Ala Val Glu Pro Ala Glu Arg Pro Ser Arg 130 135 140 Ala Arg Leu Glu Leu Arg Phe Ala Ala Ala Ala Ala Ala Ala Pro Glu 145 150 155 160 Gly Gly Trp Glu Leu Ser Val Ala Gin Ala Gly Gin Gly Ala Gly Ala 165 170 175 Asp Pro Gly Pro Val Leu Leu Arg Gin Leu Val Pro Ala Leu Gly Pro 180 185 190 Pro Val Arg Ala Glu Leu Leu Gly Ala Ala Trp Ala Arg Asn Ala Ser 195 200 205 Trp Pro Arg Ser Leu Arg Leu Ala Leu Ala Leu Arg Pro Arg Ala Pro 210 215 220 Ala Ala Cys Ala Arg Leu Ala Glu Ala Ser Leu Leu Leu Val Thr Leu 225 230 235 240 Asp Pro Arg Leu Cys His Pro Leu Ala Arg Pro Arg Arg Asp Ala Glu 245 250 255 Pro Val Leu Gly Gly Gly Pro Gly Gly Ala Cys Arg Ala Arg Arg Leu 260 265 270 Tyr Val Ser Phe Arg Glu Val Gly Trp His Arg Trp Val He Ala Pro 275 280 285 Arg Gly Phe Leu Ala Asn Tyr Cys Gin Gly Gin Cys Ala Leu Pro Val 290 295 300 Ala Leu Ser Gly Ser Gly Gly Pro Pro Ala Leu Asn His Ala Val Leu 305 310 315 320 Arg Ala Leu Met His Ala Ala Ala Pro Gly Ala Ala Asp Leu Pro Cys 325 330 335 Cys Val Pro Ala Arg Leu Ser Pro He Ser Val Leu Phe Phe Asp Asn 340 345 350 Ser Asp Asn Val Val Leu Arg Gin Tyr Glu Asp Met Val Val Asp Glu 355 360 365 Cys Gly Cys Arg 370 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 455 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..455 (D) OTHER INFORMATION: /note= "PRE-PR0 60A" (x) PUBLICATION INFORMATION: (A) AUTHORS: WHARTON, (C) JOURNAL: Proc. Natl. Acad. Sci. U.S.A. (D) VOLUME: 88 (F) PAGES: 9214-9218 (G) DATE: 1991 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Met Ser Gly Leu Arg Asn Thr Ser Glu Ala Val Ala Val Leu Ala Ser 1 5 10 15 Leu Gly Leu Gly Met Val Leu Leu Met Phe Val Ala Thr Thr Pro Pro 20 25 30 Ala Val Glu Ala Thr Gin Ser Gly He Tyr He Asp Asn Gly Lys Asp 35 40 45 Gin Thr He Met His Arg Val Leu Ser Glu Asp Asp Lys Leu Asp Val 50 55 60 Ser Tyr Glu He Leu Glu Phe Leu Gly He Ala Glu Arg Pro Thr His 65 70 75 80 Leu Ser Ser His Gin Leu Ser Leu Arg Lys Ser Ala Pro Lys Phe Leu 85 90 95 Leu Asp Val Tyr His Arg He Thr Ala Glu Glu Gly Leu Ser Asp Gin 100 105 110 Asp Glu Asp Asp Asp Tyr Glu Arg Gly His Arg Ser Arg Arg Ser Ala 115 120 125 Asp Leu Glu Glu Asp Glu Gly Glu Gin Gin Lys Asn Phe He Thr Asp 130 135 140 Leu Asp Lys Arg Ala He Asp Glu Ser Asp He He Met Thr Phe Leu 145 150 155 160 Asn Lys Arg His His Asn Val Asp Glu Leu Arg His Glu His Gly Arg 165 170 175 Arg Leu Trp Phe Asp Val Ser Asn Val Pro Asn Asp Asn Tyr Leu Val 180 185 190 Met Ala Glu Leu Arg He Tyr Gin Asn Ala Asn Glu Gly Lys Trp Leu 195 200 205 Thr Ala Asn Arg Glu Phe Thr He Thr Val Tyr Ala He Gly Thr Gly 210 215 220 Thr Leu Gly Gin His Thr Met Glu Pro Leu Ser Ser Val Asn Thr Thr 225 230 235 240 Gly Asp Tyr Val Gly Trp Leu Glu Leu Asn Val Thr Glu Gly Leu His 245 250 255 Glu Trp Leu Val Lys Ser Lys Asp Asn His Gly He Tyr He Gly Ala 260 265 270 His Ala Val Asn Arg Pro Asp Arg Glu Val Lys Leu Asp Asp He Gly 275 280 285 Leu He His Arg Lys Val Asp Asp Glu Phe Gin Pro Phe Met He Gly 290 295 300 Phe Phe Arg Gly Pro Glu Leu He Lys Ala Thr Ala His Ser Ser His 305 310 315 320 His Arg Ser Lys Arg Ser Ala Ser His Pro Arg Lys Arg Lys Lys Ser 325 330 335 Val Ser Pro Asn Asn Val Pro Leu Leu Glu Pro Met Glu Ser Thr Arg 340 345 350 Ser Cys Gin Met Gin Thr Leu Tyr He Asp Phe Lys Asp Leu Gly Trp 355 360 365 His Asp Trp He He Ala Pro Glu Gly Tyr Gly Ala Phe Tyr Cys Ser 370 375 380 Gly Glu Cys Asn Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His 385 390 395 400 Ala He Val Gin Thr Leu Val His Leu Leu Glu Pro Lys-Lys Val Pro 405 410 415 Lys Pro Cys Cys Ala Pro Thr Arg Leu Gly Ala Leu Pro Val Leu Tyr 420 425 430 His Leu Asn Asp Glu Asn Val Asn Leu Lys Lys Tyr Arg Asn Met He 435 440 445 Val Lys Ser Cys Gly Cys His 450 455 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 472 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..472 (D) OTHER INFORMATION: /note= "PRE-PR0-BMP3" (x) PUBLICATION INFORMATION: (A) AUTHORS: WOZNEY, (C) JOURNAL: SCIENCE (D) VOLUME: 242 (F) PAGES: 1528-1534 (G) DATE: 1988 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Met Ala Gly Ala Ser Arg Leu Leu Phe Leu Trp Leu Gly Cys Phe Cys 1 5 10 15 Val Ser Leu Ala Gin Gly Glu Arg Pro Lys Pro Pro Phe Pro Glu Leu 20 25 30 Arg Lys Ala Val Pro Gly Asp Arg Thr Ala Gly Gly Gly Pro Asp Ser 35 40 45 Glu Leu Gin Pro Gin Asp Lys Val Ser Glu His Met Leu Arg Leu Tyr 50 55 60 Asp Arg Tyr Ser Thr Val Gin Ala Ala Arg Thr Pro Gly Ser Leu Glu 65 70 75 80 Gly Gly Ser Gin Pro Trp Arg Pro Arg Leu Leu Arg Glu Gly Asn Thr 85 90 95 Val Arg Ser Phe Arg Ala Ala Ala Ala Glu Thr Leu Glu Arg Lys Gly Leu 100 105 110 Tyr He Phe Asn Leu Thr Ser Leu Thr Lys Ser Glu Asn He Leu Ser 115 120 125 Ala Thr Leu Tyr Phe Cys He Gly Glu Leu Gly Asn He Ser Leu Ser 130 135 140 Cys Pro Val Ser Gly Gly Cys Ser His His Ala Gin Arg Lys His He 145 150 155 Gin He Asp Leu Ser Ala Trp Thr Leu Lys Phe Ser Arg Asn Gin Ser 160 165 170 175 Gin Leu Leu Gly His Leu Ser Val Asp Met Ala Lys Ser Hi Arg Asp 180 185 190 He Met Ser Trp Leu Ser Lys Asp He Thr Gin Phe Leu Arg Lys Ala 195 200 205 Lys Glu Asn Glu Glu Phe Leu He Gly Phe Asn He Thr Ser Lys Gly 210 215 220 Arg Gin Leu Pro Lys Arg Arg Leu Pro Phe Pro Glu Pro Tyr He Leu 225 230 235 Val Tyr Ala Asn Asp Ala Ala He Ser Glu Pro Glu Ser Val Val Ser 240 245 250 255 Ser Leu Gin Gly His Arg Asn Phe Pro Thr Gly Thr Val Pro Lys Trp 260 265 270 Asp Ser His He Arg Ala Ala Leu Ser He Glu Arg Arg Lys Lys Arg 275 280 285 Ser Thr Gly Val Leu Leu Pro Leu Gin Asn Asn Glu Leu Pro Gly Ala 290 295 300 Glu Tyr Gin Tyr Lys Lys Asp Glu Val Trp Glu Glu Arg Lys Pro 305 310 315 Tyr Lys Thr Leu Gin Ala Gin Ala Pro Glu Lys Ser Lys Asn Lys Lys Lys 320 325 330 335 Gin Arg Lys Gly Pro His Arg Lys Ser Gin Thr Leu Gin Phe Asp Glu 340 345 350 Gin Thr Leu Lys Lys Ala Arg Arg Lys Gin Trp He Glu Pro Arg Asn 355 360 365 Cys Ala Arg Arg Tyr Leu Lys Val Asp phe Ala Asp He Gly Trp Ser 370 375 380 Glu Trp He He Ser Pro Lys Ser Phe Asp Ala Tyr Tyr Cys Ser Gly 385 390 395 400 Ala Cys Gin Phe Pro Met Pro Lys Ser Leu Lys Pro Ser Asn His Ala 405 410 415 Thr He £ln Ser He Val Arg Ala Val Gly Val Val Pro Gly He Pro 420 425 430 Glu Pro Cys Cys Val Pro Glu Lys Met Ser Ser Leu Ser He Leu Phe 435 440 445 Phe Asp Glu Asn Lys Asn Val Val Leu Lys Val Tyr Pro Asn Met Thr 450 455 460 Val Glu Ser Cys Ala Cys Arg 465 470 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 453 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..453 (D) OTHER INFORMATION: /note= "PRE-PR0-BMP5 (HUMAN)" (x) PUBLICATION INFORMATION: (A) AUTHORS: CELESTE, (C) JOURNAL: Proc. Natl. Acad. Sci. U.S.A. (D) VOLUME: 87 (F) PAGES: 9843-9847 (G) DATE: 1991 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Met His Leu Thr Val Phe Leu Leu Lys Gly He Val Gly Phe Leu Trp 1 5 10 15 Ser Cys Trp Val Leu Val Gly Tyr Ala Lys Gly Gly Leu Gly Asp Asn 20 25 30 His Val His Ser Ser Phe He Tyr Arg Arg Leu Arg Asn His Glu Arg 35 40 45 Arg Glu He Gin Arg Glu He Leu Ser He Leu Gly Leu Pro His Arg 50 55 60 Pro Arg Pro Phe Ser Pro Gly Lys Gin Ala Ser Ser Ala Pro Leu Phe 65 70 75 80 Met Leu Asp Leu Tyr Asn Ala Met Thr Asn Glu Glu Asn Pro Glu Glu 85 90 95 Ser Glu Tyr Ser Val Arg Ala Ser Leu Ala Glu Glu Thr Arg Gly Ala 100 105 110 Arg Lys Gly Tyr Pro Ala Ser Pro Asn Gly Tyr Pro Arg Arg He 115 120 125 Gin Leu Ser Arg Thr Thr Pro Leu Thr Thr Gin Ser Pro Pro Leu Ala 130 135 140 Ser Leu His Asp Thr Asn Phe Leu Asn Asp Ala Asp Met Val Met Ser 145 150 155 Phe Val Asn Leu Val Glu Arg Asp Lys Asp Phe Ser His Gin Arg Arg 160 165 170 175 His Tyr Lys Glu Arg Phe Asp Leu Thr Gin He Pro His Gly Glu Ala Val 180 185 190 Thr Ala Ala Glu Phe Arg He Val Lys Asp Arg Ser Asn Asn Arg Phe 195 200 205 Glu Asn Glu Thr He Lys He Ser He Tyr Gin He He Lys Glu Tyr 210 215 220 Thr Asn Arg Asp Ala Asp Leu Phe Leu Leu Asp Thr Arg Lys Ala Gin 225 230 235 240 Ala Leu Asp Val Gly Trp Leu Val Phe Asp He Thr Val-Thr Ser Asn 245 250 255 His Trp Val He Asn Pro Gin Asn Asn Leu Gly Leu Gin Leu Cys Ala 260 265 270 Glu Thr Gly Asp Gly Arg Ser He Asn Val Lys Ser Ala Gly Leu Val 275 280 285 Gly Arg Gin Gly Pro Gin Ser Lys Gin Pro Phe Met Val Ala Phe Phe 290 295 300 Lys Ala Ser Glu Val Leu Leu Arg Ser Val Arg Ala Ala Asn Lys Arg 305 310 315 320 Lys Asn Gin Asn Arg Asn Lys Ser Ser Ser His Gin Asp Ser Ser Arg 325 330 335 Met Ser Ser Val Gly Asp Tyr Asn Thr Ser Glu Gin Lys Gin Ala Cys 340 345 350 Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Gin Asp 355 360 365 Trp He He Ala Pro Glu Gly Tyr Ala Ala Phe Tyr Cys Asp Gly Glu 370 375 380 Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala He 385 390 395 400 Val Gin Thr Leu Val His Leu Met Phe Pro Asp His Val Pro Lys Pro 405 410 415 Cys Cys Ala Pro Thr Lys Leu Asn Ala He Ser Val Leu Tyr Phe Asp 420 425 430 Asp Ser Ser Asn Val He Leu Lys Lys Tyr Arg Asn Met Val Val Arg 435 440 445 Ser Cys Gly Cys His 450 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 513 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..513 (D) OTHER INFORMATION: /note= "PRE-PRO-BMP6 (HUMAN)" (X) PUBLICATION INFORMATION: (A) AUTHORS: CELESTE, (C) JOURNAL: Proc. Natl. Acad. Sci. U.S.A. (D) VOLUME: 87 (F) PAGES: 9843-9847 (G) DATE: 1991 (xi) SEQUENCE DESCRIPTION: SEQ ID N0U9: Met Pro Gly Leu Gly Arg Arg Ala Gin Trp Leu Cys Trp Trp Trp Gly 1 5 10 15 Leu Leu Cys Ser Cys Cys Gly Pro Pro Pro Leu Arg Pro Pro Leu Pro 20 25 30 Ala Ala Ala Ala Ala Ala Ala Gly Gly Gin Leu Leu Gly Asp Gly Gly 35 40 45 Ser Pro Gly Arg Thr Glu Gin Pro Pro Pro Ser Pro Gin Ser Ser Ser 50 55 60 Gly Phe Leu Tyr Arg Arg Leu Lys Thr Gin Glu Lys Arg Glu Met Gin 65 70 75 80 Lys Glu He Leu Ser Val Leu Gly Leu Pro His Arg Pro Arg Pro Leu 85 90 95 His Gly Leu Gin Gin Pro Gin Pro Pro Ala Leu Arg Gin Gin Glu Glu 100 105 110 Gin Gin Gin Gin Gin Gin Leu Pro Arg Gly Glu Pro Pro Pro Gly Arg 115 120 125 Leu Lys Ser Ala Pro Leu Phe Met Leu Asp Leu Tyr Asn Ala Leu Ser 130 135 140 Ala Asp Asn Asp Glu Asp Gly Ala Ser Glu Gly Glu Arg Gin Gin Ser 145 150 155 160 Trp Pro His Glu Ala Ala Ser Ser Ser Gin Arg Arg Gin Pro Pro Pro 165 170 175 Gly Ala Ala His Pro Leu Asn Arg Lys Ser Leu Leu Ala Pro Gly Ser 180 185 190 Gly Ser Gly Gly Ala Ser Pro Leu Thr Ser Ala Gin Asp Ser Ala Phe 195 200 205 Leu Asn Asp Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu Tyr 210 215 220 Asp Lys Glu Phe Ser Pro Arg Gin Arg His His Lys Glu Phe Lys Phe 225 230 235 240 Asn Leu Ser Gin He Pro Glu Gly Glu Val Val Thr Ala Ala Glu Phe 245 250 255 Arg He Val Lys Asp Cys Val Met Gly Ser Phe Lys Asn Gin Thr Phe 260 265 270 Leu He Ser He Tyr Gin Val Leu Gin Glu His Gin His Arg Asp Ser 275 280 285 Asp Leu Phe Leu Leu Asp Thr Arg Val Val Trp Ala Ser Glu Glu Gly 290 295 300 Trp Leu Glu Phe Asp He Thr Ala Thr Ser Asn Leu Trp Val Val Thr 305 310 315 320 Pro Gin His Asn Met Gly Leu Gin Leu Ser Val Val Thr Arg Asp Gly 325 330 335 Val His Val His Pro Arg Ala Ala Gly Leu Val Gly Arg Asp Gly Pro 340 345 350 Tyr Asp Lys Gin Pro Phe Met Val Ala Phe Phe Lys Val Ser Glu 355 360 365 Val His Val Arg Thr Thr Arg Ser Ala Ser Ser Arg Arg Arg Gin Gin 370 375 380 Ser Arg Asn Arg Ser Thr Gin Ser Gin Asp Val Ala Arg Val Ser Ser 385 390 395 Ala Ser Asp Tyr Asn Ser Ser Glu Leu Lys Thr Ala Cys Arg Lys His 400 405 410 415 Glu Leu Tyr Val Ser Phe Gin Asp Leu Gly Trp Gin Asp Trp He He 420 425 430 Ala Pro Lys Gly Tyr Ala Ala Asn Tyr Cys Asp Gly Glu Cys Ser Phe 435 440 445 Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala He Val Gin Thr 450 455 460 Leu Val His Leu Met Asn Pro Glu Tyr Val Pro Lys Pro Cys Cys Ala Pro 465 470 475 480 Thr Lys Leu Asn Ala He Ser Val Leu Tyr Phe Asp Asp Asn Ser Asn 485 490 495 Val He Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys 500 505 510 His (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 97 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..97 (D) OTHER INFORMATION: /label= Generic-Seq-7 /note= "wherein each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification." ( i) SEQUENCE DESCRIPTION: SEQ ID NO:20: Leu Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Pro Xaa Xaa Xaa Xaa Ala Xaa Tyr Cys Xaa Gly Xaa Cys Xaa Xaa Pro 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Pro 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Val Xaa Leu Xaa Xaa Xaa Xaa Xaa Met Xaa Val Xaa Xaa Cys Xaa Cys 85 90 95 Xaa (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..102 (D) OTHER INFORMATION: /label= Generic-Seq-8 /note= "vherin each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification." (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Cys Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Ala Xaa Tyr Cys Xaa Gly 20 25 30 Xaa Cys Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Cys Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Val Xaa Leu Xaa Xaa Xaa Xaa Xaa Met Xaa Val 85 90 95 Xaa Xaa Cys Xaa Cys Xaa 100 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..102 (D) OTHER INFORMATION: /label= OPX /note= "WHEREIN EACH XAA IS INDEPENDENTLY SELECTED FROM A GROUP OF ONE OR MORE SPECIFIED AMINO ACIDS AS DEFINED IN THE SPECIFICATION (SECTION II.B.2.)" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Cys Xaa Xaa His Glu Leu Tyr Val Xaa Phe Xaa Asp Leu Gly Trp Xaa 1 5 10 15 Asp Trp Xaa He Ala Pro Xaa Gly Tyr Xaa Ala Tyr Tyr Cys Glu Gly 20 25 30 Glu Cys Xaa Phe Pro Leu Xaa Ser Xaa Met Asn Ala Thr Asn His Ala 35 40 45 He Xaa Gin Xaa Leu Val His Xaa Xaa Xaa Pro Xaa Xaa Val Pro Lys 50 55 60 Xaa Cys Cys Ala Pro Thr Xaa Leu Xaa Ala Xaa Ser Val Leu Tyr Xaa 65 70 75 80 Asp Xaa Ser Xaa Asn Val Xaa Leu Xaa Lys Xaa Arg Asn Met Val Val 85 90 95 Xaa Ala Cys Gly Cys His 100 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Cleavage-site (B) LOCATION: 1..4 (D) OTHER INFORMATION: /note= "PR0TE0LYTIC CLEAVAGE SITE" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: Arg Xaa Xaa Arg 1

Claims: What is claimed is: 1. Dimeric protein comprising a pair of protein subunits associated to defined a dimeric structure having morphogenic activity, each of said subunits comprising at least a 100 amino acid sequence having a pattern of cysteine residues characteristic of the morphogen family, at least one of said subunits comprising a mature form of a subunit of a member of the morphogen family, or an allelic, species, or sequence variant thereof, noncovalently complexed with a peptide comprising a pro region of a member of the morphogen family, or an allelic, species, or sequence variant thereof to form a complex which is more soluble in aqueous solvents than the uncomplexed pair of subunits. 2. The protein of claim 1 wherein both said subunits comprise a mature form of a subunit of a member of the morphogen family or an allelic, species, or sequence variant thereof, each said subunit being noncovalently complexed with a said peptide. 3. The protein of claim 1 wherein each said subunit is the mature form of human OP-l, or a species or allelic variant thereof. 4. The protein of claim 1, 2, or 3 wherein the peptide comprises the pro region of human OP-l, or a species, allelic or sequence variant thereof. 5. The protein of claim 1 wherein said peptide comprises at least the first 18 amino acids of an amino acid sequence defining said pro region. 6. The protein of claim 1 wherein said peptide comprises at least the first 18 amino acids of an amino acid sequence defining said pro region in Seq. ID Nos. 1-16 or a sequence variant thereof. 7. The protein of claim 1 or 6 wherein said peptide comprises the full length form of said pro region. 8. The protein of claim 1 wherein said pro region peptide comprises an amino acid sequence selected from sequences defined by residues 30-48, 30-292 -and 48-292 of Seq. ID No. 1. 9. The protein of claim 1 wherein said pro region peptide comprises an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a DNA encoding the N-terminal 18 amino acids of the pro region sequences for Seq. ID Nos. 1-19. 10. The protein of claims 1 or 9 wherein said pro region peptide comprises a nucleic acid that hybridizes under stringent conditions with a DNA defined by nucleotides of 136-192 of Seq. ID No. 1 or nucleotides 157-211 of Seq. ID No. 5. 11. The protein of claim 1 wherein said subunit sequence variant comprises a chimeric morphogen amino acid sequence. 12. The protein of claim 1 wherein said peptide comprises a chimeric pro region amino acid sequence. 13. The protein of claim 1 wherein said subunit comprises a sequence defined by Generic Sequence 7 or Generic Sequence 8. 14. The protein of claim 1 wherein said subunit comprises a sequence having 60% amino acid identity with the sequence defined by residues 335-431 of Seq. ID No.l. 15. The protein of claim 1 wherein said subunit comprises the mature form of a subunit defined by any of the sequences of Seq. ID No. 5-19. 16. The protein of claim 1 wherein said subunit comprises an amino acid sequence encoded by a nucleic acid that hybridizes with a DNA defined by nucleotides 1036-1341 of Seq. ID No. 1 or nucleotides 1390-1695 of Seq. ID No. 5. 17. The protein of claim 1 further comprising an molecule capable of enhancing the stability of said complex. 18. A therapeutic composition comprising the protein of any of claims 1, 2, 5-9 or 11-17. 19. A therapeutic composition comprising the protein of claim 1 wherein each said subunit is the mature form of human OP-l, or a species or allelic variant thereof. 20. A therapeutic composition comprising the protein of claim 1, wherein said peptide comprises part or all of the pro region of human OP-l, or a species or allelic variant thereof. 21. The therapeutic composition of claim 18 comprising the protein of claim 1 wherein said subunit comprises the mature form of a subunit defined by any of the sequences of Seq. ID Nos. 5-19. 22. A therapeutic composition comprising the protein of claims 3, 4 or 10. 23. The therapeutic composition of claims 18 or 22 further comprising a cofactor. 24. The therapeutic composition of claim 23 wherein said cofactor is a symptom-alleviating cofactor. 25. A kit for diagnosing a tissue disorder or evaluating the efficacy of a therapy to regenerate lost or damaged tissue in a mammal, the kit comprising: a) means for capturing a cell or fluid sample from said mammal, b) a binding protein capable of interacting specifically with a soluble morphogen complex in said sample, and c) means for detecting the binding protein bound to said soluble morphogen complex. 26. The kit of claim 25 wherein said binding protein is an antibody. - Il l - 27. A method for evaluating the status of a tissue, the method comprising the step of comparing the quantity of morphogen in a body fluid sample with the quantity of morphogen in a control sample. 28. A method for evaluating the efficacy of a therapy to regenerate lost or damaged tissue in a mammal, the method comprising the step of comparing the quantity of morphogen in a body fluid sample with the quantity of morphogen in a control sample. 29. A method for diagnosing a tissue disorder in a mammal, the method comprising the step of comparing the quantity of morphogen in a body fluid sample with the quantity of morphogen in a control sample. 30. The invention of claim 25, 26, 27 or 28 wherein said morphogen is a dimeric protein comprising a pair of protein subunits associated to defined a dimeric structure having morphogenic activity, each of said subunits comprising at least a 100 amino acid sequence having a pattern of cysteine residues characteristic of the morphogen family, at least one of said subunits comprising a mature form of a subunit of a member of the morphogen family, or an allelic, species, or sequence variant thereof, noncovalently complexed with a peptide comprising a pro region of a member of the morphogen family, or an allelic, species, or sequence variant thereof to form a complex which is more soluble in aqueous solvents than the uncomplexed pair of subunits. 31. The invention of claims 25, 26, 27 or 28 wherein said quantity of morphogen is detected by an immunoassay. 32. The invention of claims 25, 26, 27 or 28 wherein said quantity of morphogen is detected by an antibody capable of distinguishing soluble morphogen in a sample fluid. 33. The invention of claims 25, 26, 27 or 28 wherein said body fluid sample comprises serum. 34. The invention of claims 25 or 28 wherein said tissue disorder is a bone tissue disorder. 35. The invention of claim 34 wherein said bone tissue disorder is selected from the group consisting of osteosarcoma, osteoporosis, and Paget's disease. 36. A method of evaluating the status of a tissue, the method comprising the step of detecting the presence of anti-morphogen antibody in a tissue or body fluid sample. 37. A method for evaluating the efficacy of a therapy to regenerate lost or damaged tissue, the method comprising the step of detecting the presence of anti- morphogen antibody in a tissue or body fluid sample. 38. A method for diagnosing a tissue disorder, the method comprising the step of detecting the presence of anti-morphogen antibody in a tissue or body fluid sample. 39. A kit for diagnosing a tissue disorder or evaluating the efficacy of a therapy to regenerate lost or damaged tissue in a mammal, the kit comprising: a) means for capturing a cell or fluid sample from said mammal; b) a binding protein capable of interacting specifically with an endogenous anti-morphogen antibody in said sample; and c) means for detecting said binding protein-bound to said endogenous anti-morphogen antibody.

Inventors: JONES WILLIAM K, KUBERASAMPATH THANGAVEL, OPPERMANN HERMANN, OZKAYNAK ENGIN, RUEGER DAVID C, TUCKER RONALD F, JONES, WILLIAM, K., KUBERASAMPATH, THANGAVEL, OPPERMANN, HERMANN, OZKAYNAK, ENGIN, RUEGER, DAVID, C., TUCKER, RONALD, F.
Applicants: CREATIVE BIOMOLECULES INC, CREATIVE BIOMOLECULES, INC.
Application year: 1993
Main classification: C12N15
IPC codes: A61F2, A61K6, A61K38, A61K39, A61K48, A61L27, A61P43, C07K14, C07K16, C12N15, C12P21, G01N33